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MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN VETERANS: A 
STUDY ACCORDING TO HOSPITAL SOPHISTICATION. Jody A. Levine and 
Michael D. Ezekowitz. Section of Cardiology, Department of Internal Medicine, Yale 
University, School of Medicine, New Haven, CT. 
Employing baseline data from the CHAMP study, a prospective, randomized study of 5018 
patients post acute myocardial infarction (AMI), conducted in the VA to evaluate aspirin/warfarin in 
combination versus aspirin, we investigated whether a relationship existed between the availability of 
resources and the type of medical care delivered. In addition, we assessed for temporal trends in 
pharmacologic treatment to determine if practice patterns reflect the results of clinical trials. Accordingly, 
participating hospitals were divided into three groups: group 1 did not perform cardiac catheterization 
procedures, angioplasty (PTCA), or cardiovascular surgery (CABG); group 2 performed cardiac 
catheterization procedures, but not PTCA or CABG; group 3 provided PTCA and CABG. Procedure and 
pharmacologic use were examined for each hospital group and plotted overtime (1993-1997). 
Patients admitted to group 3 hospitals were more likely to undergo “early” (within 14 days of 
AMI) PTCA (23.4%) as compared with other interventions, i.e., “later” (14-90 days after AMI) PTCA 
(8.8%), “early” CABG (7.69%), and “later” CABG (14.64%). The rate of “early” PTCA increased with 
increasing hospital sophistication: 5.04%, 8.55%, and 23.45% in groups 1, 2, and 3, respectively 
(p=0.001). For group 1, “later” CABG was more common compared with groups 2 and 3: 19.16% vs. 
13.00% vs. 14.64%, respectively (p=0.001). In all hospital groups utilization rates of beta-blockers, 
ACE inhibitors, and hypolipidemic agents increased, while use of calcium channel blockers decreased 
(p=0.001 for each drug). 
We conclude that procedure use in VA patients with AMI increased overtime (1993-1997) and 
differed by level of hospital sophistication: greater “early” PTCA rate in sophisticated and greater “later” 
CABG rate in patients admitted to unsophisticated hospitals. The impact of these findings will be better 
understood when outcome analyses are performed. Trends in pharmacologic treatment provide evidence 
that clinical trial results are being translated into patient care. 
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In this age of rapidly changing technology and advances in pharmacological 
therapy, increasing emphasis is being placed on analyzing our medical care system, its 
appropriateness and effectiveness. The Veterans Administration (VA) system , our largest 
national health system, is a particularly useful marker of our medical care system at large, 
isolating the medical care system from the variables of patients or doctors involved. The 
VA system serves a patient population that is sociodemographically homogeneous, has a 
highly centralized administrative structure, and contains physicians that are salaried and 
thus unable to maximize their revenue by altering their practice patterns. These factors 
make the VA system an excellent model for the evaluation of medical care practices. 
Increased analysis of the VA health care system, over the last several years, has resulted, as 
well, from a heightened commitment by the Department of VA health care toward 
revamping its structure in order to assure greater quality and efficiency of care. 
In this study we employ data from the VA health care system to assess 
management patterns in patients diagnosed with acute myocardial infarction. We 
investigate the question of how patient care is dependent on the resources that are available- 
-how hospital sophistication impacts medical practice patterns. In order to provide 
background to the treatment options available in the management of AMI, we first provide 
an extensive review of the literature. Standards of care are presented as ACC/AHA 
guidelines. 
Another focus of this thesis is to determine whether the medical management 
employed by the VA health care system adheres to these clinical practice guidelines. 
Large, well-designed clinical trials have been conducted over several decades in patients 
with ischemic heart disease. Many have provided definitive results which have been 
translated into published guidelines, designated to provide standards for optimum patient 
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care. A number of organizations have developed such guidelines, including the American 
College of Cardiology (ACC) and the American Heart Association (AHA), in a joint effort. 
Clinical guidelines are of growing importance as technology rapidly progresses and there is 
a need to curb the cost of medical care; for, if adopted, they should impact the cost of 
medical care without diminishing its effectiveness. Guidelines are also meaningful for legal 
reasons as well as for payment of physicians from third party carriers. 
Despite the effort that has been dedicated toward clinical trials and subsequent 
guidelines, translation of these studies and applications of guidelines in clinical practice is 
imperfect. There is evidence of a gap between how we actually manage and how we 
should be managing patients with ischemic heart disease. This study will, in part, 
investigate this concern. By accruing data over a six year time period, we study changes in 
practice patterns over time. We assess whether temporal trends in management of acute 
myocardial infarction (AMI) reflect the clinical trial results that were published during the 
time period under investigation. Since the results of clinical trials are ultimately translated 
into guidelines, our analysis will help to evaluate if the aforementioned gap exists in the VA 
system. 
B. Acute Myocardial Infarction 
1. Definition 
A spectrum of clinical conditions ranging from unstable angina to non-Q wave AMI 
and Q wave AMI is referred to as “the acute coronary syndrome.” Patients that present 
with ischemic chest pain at rest can be divided into those that show ST-segment elevation 
on initial 12-lead EKG and those that have no ST- segment elevation. There is a high 
probability that patients with ST-segment elevation have a thrombus occluding the “infarct- 
related” coronary artery and the majority of these patients develop a Q wave AMI. 
Nonetheless, not every ST elevation MI becomes a Q wave AMI and a minority of these 
patients do develop a non-Q wave AMI. Depending on the existence of serum cardiac 
markers such as CK-MB, patients that present initially without ST elevation usually are 
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diagnosed as either having a non-Q wave AMI or having unstable angina. A minority of 
these patients ultimately develop a Q wave AMI. Clinical distinction among these entities is 
retrospectively achieved following serial EKGs and serum cardiac markers. Acute 
myocardial infarction is generally considered the prime example of the acute coronary 
syndrome and is the entity on which we will focus from here on [1]. 
2. Incidence 
Coronary artery disease is the single largest killer of males and females in the 
United States [2]. Approximately 1.5 million myocardial infarctions occur each year in the 
United States with a mortality rate of approximately 30%. Greater than half of these deaths 
occur before the individuals reach the hospital [3]. The American Heart Association 
statistics show that about every 29 seconds an American will suffer a coronary event, and 
about every minute someone will die from one. There are 13,900,000 people alive today— 
7,100,000 males and 6,800,000 females—with a history of heart attack, angina pectoris or 
both [2]. 
Despite a 47% reduction in age-adjusted coronary mortality rates over the previous 
20 years, 514,000 people died of coronary disease in 1987 [4]. In 1995, coronary disease 
caused 481,287 deaths in the US—1 of every 4.8 deaths—and yet a decline in death rate of 
28.7% from 1985. Among the patients who died from coronary disease in 1995, 244,819 
(50.9%) were male and 236,468(49.1%) female. Death rates in 1995 from coronary 
disease were 124.4 for white males and 133.1 for black males (7.0% higher), 60.3 for 
white females and 81.6 for black females (35.3 % higher) [2]. 
Although the mortality rate following admission for myocardial infarction has 
encouragingly declined by about 30 % over the last two decades, approximately 1 of every 
25 patients who survives initial hospitalization will die in the first year following 
myocardial infarction [31. People who survive the acute stage of a heart attack have a 
chance of illness and death that is 2-9 times higher than that of the general population. The 
risk of another heart attack, sudden death, angina pectoris, heart failure and stroke, for both 
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men and women, is substantial [2]. For elderly patients (over age 65), survival is 
markedly decreased with a mortality rate of 20 percent at 1 month and 35 percent at 1 year 
following infarction [3]. 
3. Etiology, Classification, and Outcome 
Myocardial infarction is caused by prolonged myocardial ischemia, usually 
precipitated by an occlusive coronary thrombus at the position of a preexisting, though not 
always flow limiting, atherosclerotic plaque. Other, less frequent causes include prolonged 
vasospasm, insufficient myocardial blood flow (i.e., hypotension), or excessive metabolic 
demand. Rarer etiologies include occlusion by an embolus, vasculitis, aortic root or 
coronary artery dissection, or aortitis. In young individuals with no cardiac risk factors, 
cocaine may be the culprit. 
The site and magnitude of infarction depend upon the distribution of the occluded 
vessel, the existence of additional stenotic lesions, and the sufficiency of collateral 
circulation. Classic electrocardiographic findings of the evolution of ST segment elevation 
to Q-waves marks the infarction as transmural. If pain, enzyme elevations, and ST-T wave 
changes occurred without Q-waves, however, the infarction is termed nontransmural or 
subendocardial. On pathologic examination infarctions primarily involve the 
subendocardium, with some transmural extension, even in the absence of Q-waves. Thus, 
the classification of infarctions as Q-wave versus non-Q-wave is more appropriate. The 
latter type of infarction is linked with a greater incidence of reinfarction and recurrent 
ischemia as it usually results from partial occlusion or spontaneous lysis of the thrombus, 
leaving additional myocardium in danger. 
The outcome of infarction, both immediate and long-term is related to the extent and 
anatomic location of the infarction. Hemodynamic results post-MI depend on the extent of 
necrosis as well as the presence (or absence) of any previous damage. Cardiac function can 
range from normal in small infarctions, to failure and hypotension (cardiogenic shock) with 
more damaging episodes. Collateral circulation and blood flow through a partially 
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occluded vessel are often responsible for supplying nearby myocardium, placing this tissue 
at risk. Thus, early management must focus on curbing infarct expansion [5]. 
4. Developments in Treatment 
In 1912 the myocardial infarction syndrome was first related to coronary 
thrombosis. From that time through the 1940s, the introduction of oral anticoagulant 
therapy was the only change in treatment-a slow progression. Coronary care units were 
developed in the late 1950s. In the 1960s direct current defibrillators and closed chest 
cardiopulmonary resuscitation made a significant impact on the early mortality rate of 
myocardial infarction. Hemodynamic monitoring of myocardial infarction patients and the 
recognition that hypovolemia is a correctable cause of shock in some of these patients 
began in the 1960s as well. The development of counterpulsation minimally improved the 
survival in patients with pump failure. In the 1970s, greater universal training began in 
cardiopulmonary resuscitation, as did placement of mobile coronary care units. 
Pharmacologic methods for preservation of the myocardium were initiated in the 1970s 
with improvement of myocardial nutrient supply through interstitial diffusion with 
hyaluronidase or glucose-insulin-potassium solution. Beta-adrenergic blockers and 
unloading agents were employed as well, to decrease myocardial oxygen requirements [4]. 
The next major step was with reperfusion through early coronary artery bypass 
surgery, provided by physicians in Spokane, Washington [6]. Convincing evidence was 
provided by DeWood et al that the thrombus formed in the coronary artery early in 
myocardial infarction was likely to spontaneously lyse in some patients over the subsequent 
hours [7]. Although this surgical approach was not widely adopted due to logistic 
impracticality, the surgical experiences in Spokane and later Iowa [8] were leaders in 
reperfusion by surgical thrombectomy and coronary bypass. 
Chazov et al. [9] presented data on intracoronary fibrinolysis in acute myocardial 
infarction in 1976. Rentrop et al. [10] mechanically opened the artery and then used 
intracoronary thrombolytics to accomplish catheter-directed reperfusion. The era of routine 
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thrombolysis in patients with acute myocardial infarction began with the Gruppo Italiano 
per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) trial [11], the first large 
study of early intravenous thrombolysis. Second generation thrombolytic agents which are 
more clot specific and third generation agents, possibly represented by a single chain pro¬ 
urokinase, may well improve the safety and efficacy of thrombolysis. 
C. ACC/AHA Clinical Practice Guidelines: History And Format 
In 1980 the American College of Cardiology (ACC) and the American Heart 
Association (AHA) joined together to form a “Task Force on the Assessment of Diagnostic 
and Therapeutic Cardiovascular Procedures.” The motivating goal was to examine the 
impact of the vastly expanding technology on the cost and practice of medicine and thus 
impact the cost of medical care without sacrificing its effectiveness. The ACC/AHA 
“Guidelines for the Early Management of Patients With Acute Myocardial Infarction” was 
introduced in 1990 to summarize recent advances and provide guidelines for appropriate 
patient management following acute MI. Ultimate decisions regarding patient care, 
however, should be made by the physician and patient according to clinical judgment and 
individual patient needs [4]. 
The ACC/AHA guidelines provide expert opinion and the evidence for a given 
diagnostic procedure, therapy, or intervention using the following format [1]: 
Class I: Conditions for which there is evidence and/or general agreement that a 
given procedure or treatment is beneficial, useful, and effective. 
Class II: Conditions for which there is conflicting evidence and/or a divergence of 
opinion about the usefulness/efficacy of a procedure or treatment. 
Class Ha: Weight of evidence/opinion is in favor of usefulness/efficacy 
Class lib: Usefulness/efficacy is less well established by evidence/opinion. 
Class III: Conditions for which there is evidence and/or general agreement that a 
procedure/treatment is not useful/effective and in some ways may be harmful. 
D. Treatment Options 
1. Thrombolysis 
a. Rationale for Thrombolytic Therapy 
Complete occlusion may result from rupture of an unstable plaque within a 
coronary artery. AMI and resulting left ventricular dilation can then occur, potentially 
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leading to complete heart failure, electrical instability and death. Lysing the clot as soon as 
possible, either with thrombolysis or primary PTCA, will decrease the extent of left 
ventricular dysfunction and dilation, lowering the chance of heart failure and harmful 
arrhythmia. Even reperfusion after 4 to 6 hours have passed has beneficial effects. Such 
late reperfusion can positively affect infarct healing and decrease remodeling of the left 
ventricle, systolic dysfunction, and electrical instability [12]. 
b. General Mechanisms of Action 
All thrombolytics to date share some common features. They all act either directly 
or indirectly to enzymatically convert plasminogen to plasmin which in turn cleaves fibrin 
thus lysing thrombi. Plasminogen, a single chain molecule is cleaved at the arginine 560- 
valine 561 location forming plasmin, a double chain molecule and exposing plasmin’s its 
active site. Plasmin can then serve as a serine protease that hydrolyzes fibrin and dissolves 
the clot [1, 13]. 
In each case, clot dissolution and subsequent reperfusion occur with a higher 
frequency when therapy is initiated early after clot formation, since clots become more 
resistant to lysis as they age. Unfortunately, increased local thrombin may occur as the clot 
dissolves, leading to enhanced platelet aggregatabiltity and thrombosis. Strategies to 
prevent this include administration of antiplatelet drugs such as aspirin, or antithrombotics 
such as heparin. 
Differences among thrombolytic agents include their specificity for clot-bound 
fibrin versus circulating fibrin, their half life, rate of action, bleeding risks and expense. 
The first agents to be approved, streptokinase and urokinase, cause a systemic fibrinolytic 
state that can lead to bleeding problems. Alteplase, also known as tissue-type plasminogen 
activator (tPA), acts more locally on the thrombotic fibrin to produce fibrinolysis, and is a 
potentially important agent in treating thromboembolic disease. Clinical experience has 
shown about equal efficacy between streptokinase and tPA. Recent trials have led to a 
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quicker tPA administration-dose applied over 90 minutes rather than 180—leading to earlier 
thrombolysis without increased bleeding risk. 
The clinical gains that amass from increased patency of the “infarct-related” vessel 
in those treated with thrombolytic agents include less left ventricular failure, reduction in 
fatal arrhythmias, a decreased number of serious complications such as septal rupture and 
cardiogenic shock, and decreased mortality. Several studies following patients for up to 
five years after thrombolytic therapy reveal improvements in both short and long-term 
survival. This therapy, however, is still in need of improvement, as rates of in-patient re¬ 
occlusion have been reported to be as high as 10%, increasing to 30 % by 3 months. 
Additionally, re-infarction is a possibility, occurring in up to 5% of in-patients and 7% of 
thrombolytic-treated patients within the first year [12]. 
c. Adverse Effects 
Bleeding is a major adverse effect of thrombolytic therapy as these agents are 
equally likely to dissolve the fibrin of a dangerous thrombus as they are to dissolve the 
fibrin of a much needed hemostatic plug. Occult lesions, such as a peptic ulcer, may bleed 
subsequent to thrombolytic therapy. Therefore, thrombolytics are contraindicated in 
patients who have a healing wound, a history of stroke, metastatic cancer, or who are 
pregnant. After the initial clot is lysed, rethrombosis is possible if thrombogenic stimuli 
still exist [13]. 
d. Overview of Clinical Trials 
Large, well-designed clinical trials have established that thrombolytics successfully 
improve outcome post-AMI and positively affect both myocardial salvage and remodeling. 
An extensive survey of nine trials involving thrombolytic therapy, each trial including more 
than 1000 patients, was performed by The Fibrinolytic Therapy Trialists’ (FTT) 
Collaborative Group [14]. Cumulative data from the 58,600 enrolled patients revealed that 
relative to standard medical treatment, thrombolytic therapy offers a highly significant 21% 
reduction (p<0.00001) in 35-day mortality among AMI patients with ST elevation on initial 
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EKG. This corresponds to an absolute reduction of 21 deaths per 1000 patients treated. In 
contrast, the patients presenting with ST segment depression had only an 11 % reduction in 
mortality. This excess mortality serves as part of the basis for the perception that 
thrombolytic therapy does not benefit patients presenting with ST segment depression [ 1 ]. 
Interestingly, the ISIS-2 study [15], the largest of the studies included in the FTT 
analysis, revealed a 53% reduction in mortality when aspirin and streptokinase were 
administered together within 4 hours of AMI compared with control (6.4% vs. 13.1%, 
P=0.0001). 
A definite time-dependent effect of thrombolytic therapy on mortality was disclosed 
in these studies. With regard to the time elapsed from the onset of symptoms until 
thrombolysis was initiated, 35 lives were saved per 1000 for 0-1 hour, 25 lives per 1000 
were saved for 2-3 hours, 19 lives were saved per 1000 for 4-6 hours, and 16 lives were 
saved per 1000 for 7-12 hours. Thrombolysis administered within 6 hours of symptom 
onset results in the highest success rates. Collectively these data indicate that benefit exists 
from thrombolytic therapy if it is initiated within 12 hours from the onset of symptoms [12] 
. In addition, composite results from two other trials, LATE [16] and EMERAS [17], 
show that thrombolytics initiated between 6 and 12 hours from the start of ischemic 
symptoms may still provide a reduction in mortality. Hence, the “window” of treatment 
with thrombolytics has been defined to be within 12 hours from the onset of ischemic 
symptoms [1,12]. 
e. Recommendations [l. 12]: 
Class I 
1. ST elevation (greater than 0.1 mV, two or more contiguous 
leads)1, time to therapy 12 hours or less2, age less than 75 years. 
1 Repeat ECGs recommended during medical observation in effective clinical settings 
when initial ECG is nondiagnostic of ST elevation. 
2 Time of symptom onset is defined as the beginning of continuous, persistent discomfort 
that brought the patient to the hospital. 
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2. Bundle branch block (obscuring ST-segment analysis) and 
history suggesting acute MI 
Class Ila 
1. ST elevation , age 75 years or older. 
Class lib 
1. ST elevation , time to therapy greater than 12 to 24 hours . 
2. Blood pressure on presentation greater than 180 mm Hg systolic 
and/or greater than 110 mm Hg diastolic associated with high-risk MI. 
Class III 
1. ST elevation , time to therapy greater than 24 hours , ischemic 
pain resolved. 
2. ST depression only. 
f. Contraindications and Cautions 
As mentioned previously, the most substantial risk of thrombolytic therapy is 
hemorrhage, especially intracranial hemorrhage (ICH), which can be fatal in greater than 
half to two thirds of patients. The risk of stroke from thrombolytics is strongest within the 
first day of therapy. Clinical variables to be assessed in the emergency department which 
predict a higher risk of intracranial hemorrhage include age above 65 years (odds ratio 2.2, 
95% Cl, 1.4-3.5 ), body weight below 70 kg (odds ratio 2.1, 95% Cl 1.3-3.2), 
hypertension on„presentation (odds ratio 2.0, Cl 1.2 to 3.2 ), and t-PA use (odds ratio 1.6, 
95% Cl 1.0 -2.5). 
g. Summary 
In summary, thrombolysis is favorable for all patients, irrespective of age, gender, 
and the existence of comorbidities such as diabetes mellitus, although the extent of benefit 
does differ among patient groups. When compared with routine medical therapy in AMI- 
patients with ST elevation, thrombolytics reduce 35-day mortality by 21%. The effects of 
thrombolytics are time dependent with the strongest benefits obtained when administered 
within 6 hours from the onset of ischemic symptoms. Therapy within 12 hours from 
symptom onset, however, is also beneficial. A slightly elevated risk of intracranial 
hemorrhage is associated with thrombolysis, generally occurring within the first 24 hours 
of thrombolytic therapy. Risk factors for ICH include age above 65, body weight below 70 
kg, hypertension and tPA therapy [1, 12]. 

2. Primary Percutaneous Transluminal Coronary Angioplasty (PTCA) 
a. General Considerations 
Another option for reperfusion therapy in AMI patients, in place of thrombolysis, is 
primary PTCA. This procedure begins with the patient undergoing immediate 
angiography—injection of radioopaque contrast medium followed by radiography of vessels 
[18]. Primary angiography is accompanied by PTCA which involves dilation of coronary 
artery stenosis by balloon inflation under high pressure. This procedure should be done as 
soon as possible, for using a guidewire and balloon to traverse a complete occlusion caused 
by recent thrombus is much easier than trying to cross a hardened, well- established one. 
Atheromatous plaque is ruptured and intraluminal debris resorbed. The patient is given 
local anesthesia and the procedure is carried out in the cardiac catheterization laboratory at 
the time of diagnostic arteriography or later. 
When wire guided balloon angioplasty is used for reperfusion in place of 
thrombolytics this is called “direct or primary angioplasty.” Other applications of PTCA 
include its use as an adjunct to thrombolysis or for management of patients who did not 
receive thrombolytics and are now in the subacute stage (2-7 days) post MI. “Rescue” 
PTCA may be performed right away if thrombolytics were not successful or if the patient 
has a extreme stenosis in the infarct-related vessel. Strategies have been mentioned for 
people with residual stenosis > 70% following thrombolysis to have “immediate” PTCA— 
within a few hours, or “deferred”—within the next seven days. “Elective” PTCA is another 
approach in which an AMI patient, independent of previous thrombolytic therapy, 
undergoes angioplasty because of exercise induced or spontaneous ischemia [12]. 
The best lesions for PTCA are relatively proximal, noneccentric, without major 
calcification or plaque dissection, and not at the origin of large branches. The main early 
complication of this procedure is intimal dissection and vessel blockage. If this occurs, 
repeat PTCA or placement of an intracoronary stent can resolve the situation. In 1-2% of 
cases, CABG is required and therefore must be available in a center performing PTCA. 

12 
Restenosis, although susceptible to treatment with repeat PTCA is the major limitation to 
this method, occurring in 30-40% of vessels dilated after the first 6 months. 
Intracoronary stent placement seemingly reduces the incidence of restenosis. At 
first, aggressive anticoagulation was used following stent placement to avoid the small risk 
of acute thrombosis. However, the present regimen, including high pressure balloons and 
intravascular ultrasound for placement followed by antiplatelet therapy with aspirin and 
ticlopid has lead to an acute thrombosis rate of below 1 %. Stents are currently used in 
greater than 30% of PTCA procedures in the US [5]. 
While the ensuing discussion will focus on the use of primary PTCA, secondary 
PTCA plays an important role in post-MI treatment as well. Although some physicians will 
perform angiography and PTCA on all patients following AMI, present data show that this 
routine will not salvage myocardium or reduce the likelihood of reinfarction or death. 
Instead, this management strategy should be reserved for patients who have had an AMI 
and now have good left ventricular (LV) function but spontaneous or provoked ischemia [1| 
. Additionally, acute catheterization and PTCA or CABG is appropriate in patients with 
cardiogenic shock and in patients with hemodynamic compromise (systolic blood pressure 
> 100 mm Hg [5]. 
b. Overview Of Clinical Trials 
Meyer et al [19], in 1982, were first to publish data on the use of primary PTCA 
rather than thrombolysis in AMI patients. Since then the issue has been the source of much 
debate. Being that there are no randomized clinical trials comparing direct PTCA to no 
reperfusion, recommendations are based on indirect evidence and on medium-sized trials 
that compare thrombolysis vs. PTCA. 
Initially, it was shown that greater than 90% of the time, PTCA successfully 
restored forward flow in the “infarct-related” vessel and had a 90-96% 1-year survival rate. 
In subsequent studies comparing PTCA to thrombolysis, post -AMI, PTCA restored 
forward flow about 88-95% of the time [1]. Using angiography several weeks after MI, 
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Zijlstra et al [20], in 1993, showed that patients who had been treated with PTCA had a 
91% rate of having a patent “infarct-related” artery while those who had undergone 
thrombolysis had only a 68% patency rate (P=.001). Stenosis was also greater in the 
thrombolytic patients. Adverse in-hospital outcomes such as nonfatal infarction, recurrent 
ischemia, the need for coronary revascularization, and death were decreased among PTCA 
treated patients. 
A meta-analysis proposes that PTCA, as compared to thrombolysis, will reduce the 
probability of recurrent ischemia and thereby reduce ensuing hospital morbidity, 
hospitalization and expenses [21]. This advantage, however, is in exchange for performing 
PTCA on all patients post MI (rather than just the 20% to 40% who actually need 
recanalization following thrombolysis). 
c. Limitations 
Despite the above evidence that PTCA may be preferable to thrombolysis in post- 
AMI treatment, it is important to consider that only 20% of United States hospitals have the 
necessary catheterization equipment, and even less have the ability to do emergency PTCA. 
The time delay that would be involved in transferring a patient to a facility that does have 
the aforementioned capabilities may outweigh the benefits of PTCA. 
In addition, the superb results obtained in clinical trials with the use of PTCA may 
not be reproducible in the community, as the physicians involved in these studies have been 
exceptionally experienced in performing PTCA and dedicated to adhering to the protocol 
with every step. Additionally, time was not a limiting factor in these studies as PTCA was 
performed within 60-90 minutes from patient arrival (the recommended time frame being 
that balloon dilation should occur within 60-90 minutes of AMI diagnosis). In recent 
community-based registries in the United States and Europe the time elapsed between 
patient arrival to the hospital and PTCA had been greater than the time needed until 
thrombolytic infusion. These registries show a similar in-hospital mortality for patients 
treated with both therapies. 
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In addition to the issue of institution capability and time delay, 2%-5% of patients 
who undergo PTCA will require emergency CABG, either because of an artery that was 
not appropriate for PTCA or because failed angioplasty dictates further surgical treatment. 
Thus PTCA can only be performed in hospitals with CABG capabilities or definite plans 
for immediate access to another facility with this proficiency [1]. 
d. Recommendations [1]: 
Class I 
1. As an alternative to thrombolytic therapy only if performed in a 
timely fashion by individuals skilled in the procedure3 and supported by 
experienced personnel in high-volume centers4. 
Class Ha 
1. As a reperfusion strategy in patients who are candidates for reperfusion 
but who have a risk of bleeding contraindication to thrombolytic therapy. 
2. Patients in cardiogenic shock 
Class lib 
1. As a reperfusion strategy in patients who fail to qualify for thrombolytic 
therapy for reasons other than a risk of bleeding contraindication. 
e. Summary 
Primary PTCA is a good alternative to thrombolytic therapy if the timing is right 
and appropriately skilled personnel are available. Additionally, one should be certain of 
direct availability of emergency CABG surgery before engaging in primary PTCA [l]. 
3. Coronary Artery Bypass Graft Surgery (CABG) 
a. General Considerations 
The technique of surgical revascularization by CABG includes establishing vascular 
grafts and bypassing the occlusion. Grafts using one or both internal mammary arteries, 
generally to the left anterior descending artery or its branches, lead to the best long term 
patency and flow results. One can also create a graft connecting a segment of the 
saphenous (or, less favorably, other veins) from the aorta to the occluded coronary artery, 
distal to the area of obstruction. One to five distal anastomoses are common [5]. In 
patients who require revascularization within 48-72 hours post AMI, PTCA is still the 
3 Individuals who perform more than 75 PTCA procedures per year. 
4 Centers that perform more than 200 PTCA procedures per year. 
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preferable method. Surgery, however is indicated in the patient who was unsuccessfully 
treated with PTCA or who has the high risk coronary anatomy appropriate for CABG- 
stenosis of the left main coronary artery (above 50%), three vessel disease, disease in two 
vessels plus involvement of the left anterior descending artery proximally, disease in two 
vessels that is not appropriate for PTCA, and decreased ejection fraction, left main 
coronary artery disease or expansive, multivessel involvement. 
Patients with the appropriate anatomy show an increased long-term survival from 
elective CABG following MI. Retrospective studies suggest that if CABG is performed 3-7 
days following MI, mortality is similar to that of other elective CABG procedures. The 
operative risk is increased in patients with emergency surgery, increased age and reduced 
ventricular function. 
The majority of patients who undergo CABG following AMI—about 10-20 % of 
AMI patients— undergo the procedure due to chest pain that will not remit or is recurrent 
despite thrombolysis or PTCA, the appropriate coronary anatomy revealed by 
catheterization, or a complication following AMI such as papillary muscle dysfunction 
leading to severe mitral regurgitation or ventricular septal rupture. Severe hemodynamic 
and ischemic instability that persists following AMI also dictates a situation in which the 
patient should have surgical revascularization. 
Emergency cardiac surgery in AMI carries an approximately 2% in-hospital and 
25% 10-year mortality rate in certain centers. This success is due to advanced surgical 
techniques and enhancement in cardioplegia and hypothermia mechanisms resulting in 
greater cardiac preservation during bypass surgery. Similar to other methods intended to 
impede further infarct, myocardial salvage is most efficient if the surgery is performed 
within the first 4-6 hours following onset of AMI. However, given the amount of time 
that is feasibly required to carry out the various steps needed from the time an out-patient 
experiences symptoms to the time one can operate, it is not likely that this will become a 
standard method of treatment. In fact, operating on a patient with an uncomplicated Q- 
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wave infarct more than six hours after onset has been shown to increase hemorrhage to the 
infarct area and is thus contraindicated in this scenario. The only group that may benefit 
from CABG greater than six hours after onset of AMI are patients, including those in 
cardiogenic shock, in whom the infarct occurs in a stunning fashion (i.e., over several 
days). This benefit, however, has not been definitively established. 
Emergency operation in a patient with active and persistent ischemia or cardiogenic 
shock increases the operative mortality. Surgeries , however, that take place more than 24 
hours after AMI in patients who have had successful thrombolysis but still have stenosis 
and are anatomically more suitable for CABG than PTCA have a mortality rate of about 
4%. Autopsy studies have found that hemorrhagic necrosis is extensive in these patients. 
If a patient has had thrombolysis within the last 6-12 hours and now requires CABG, the 
patient’s coagulation system must be repleted with aprotinin and fresh-frozen plasma. 
There is an increase in minor bleeding and postoperative chest tube drainage following 
emergency CABG relative to an elective procedure but these do not represent a primary area 
of concern [12]. 
b. Recommendations for Emergency or Urgent CABG [1] : 
Class I 
1. Failed angioplasty with persistent pain or hemodynamic 
instability in patients with coronary anatomy suitable for surgery. 
2. Acute MI with persistent or recurrent ischemia refractory to 
medical therapy in patients with coronary anatomy suitable for surgery who 
are not candidates for catheter intervention. 
3. At the time of surgical repair of postinfarction VSD or mitral 
valve insufficiency. 
Class Ha 
1. Cardiogenic shock with coronary anatomy suitable for surgery. 
Class lib 
1. Failed PTCA and small area of myocardium at risk; 
hemodynamically stable. 
Class III 
1. When the expected surgical mortality rate equals or exceeds the 




In summary, prior to the successful development of thrombolytic agents and PTCA 
for coronary reperfusion, studies that compared AMI patients treated with CABG vs. 
controls indicated that emergency CABG patients had a better chance of living longer and a 
higher percentage of rescued myocardial tissue. Given the surgical nature of this 
procedure, CABG use is mostly in situations where other therapies have been unsuccessful 
or inadvisable in AMI patients. Overall, there are four situations where immediate surgical 
intervention is advised: (1) the patient had unsuccessful PTCA and now suffers from 
persistent chest pain or hemodynamic instability; (2) the patient that is not a candidate for 
catheterization but has persistent or recurrent ischemia that is refractory to medical 
management; (3) the patient who is in cardiogenic shock but can’t undergo PTCA because 
of unsuitable anatomy; and (4) the patient with a mechanical dysfunction5 causing severe 
pulmonary congestion or hypotension should also have surgical intervention [1]. 
E. Rationale and Approach to Pharmacotherapy 
1. Nitroglycerin 
a. General considerations and Mechanism of Action 
Organic nitrates (and nitrites) are simple nitric and nitrous esters of alcohols. They 
all rapidly reduce myocardial oxygen demand and thus rapidly relieve symptoms. 
Nitrates, beta-blockers and calcium channel blockers are all appropriate for use to relieve 
anginal pain. However, nitroglycerin, sublingual or spray form, is the drug of choice for 
prompt relief of an anginal attack brought on by exercise or emotional stress. 
The principal action of nitrates is vasodilation, mostly via inducing relaxation of 
vascular smooth muscle in veins, arteries, and arterioles. Nitroglycerin and other organic 
nitrates convert to nitrite ions intracellularly. They then convert to nitric oxide (NO) which 
in turn activates guanylate cyclase and raises the amount of cyclic GMP within the cell. 
Elevated cGMP leads to dephosphorylation of the myosin light chain and ultimately results 
5 Examples include a papially mucsle rupture causing mitral regurgitation or a ventricular septal defect. 
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in relaxation of vascular smooth muscle [13]. Nitric oxide, also known as endothelium- 
derived relaxing factor (EDRF), is an important modulator of vascular tone which is 
endogenously produced. In patients with coronary artery atherosclerosis, however, it is 
believed that endogenous stores are depleted and thus exogenous administration in the 
forms of nitrates is needed [1]. 
Nitroglycerin decreases cardiac work and thereby decreases myocardial oxygen 
demand. At therapeutic doses its two major effects include the dilation of the coronary bed 
and the dilation of large veins, especially in the splanchnic and mesenteric circulations, 
causing pooling of blood in the veins. The former action increases blood supply to the 
myocardial tissue while the latter action diminishes venous return of blood to the heart 
(preload) and therefore reduces the work of the heart [13]. Nitroglycerin will also decrease 
afterload by causing arterial vasodilation. The combined decrease in right and left 
ventricular preload as well as afterload reduction greatly decreases the work of the heart and 
reduces oxygen demand. Myocardial ischemia is relieved as the ratio of myocardial oxygen 
demand to myocardial oxygen supply decreases. Patients with impaired LV systolic 
function or CHF especially benefit from nitrates. Additionally, nitrates increase the 
subendocardial-epicardial blood flow ratio by not only causing direct vasodilation of the 
coronary vasculature but also by inducing prevention of occasional vasoconstriction of 
coronary arteries. Some atherosclerotic lesions which have intact vascular smooth muscle 
are widened, increasing the caliber of arterial openings and increasing flow. Other actions 
of nitrates include their ability to dilate coronary collateral vessels, decrease the 
vasoconstriction of small coronary arteries distal to the point of obstruction and lower 
platelet aggregation [1]. 
b. Fimitations and Adverse Effects 
Headache is the most common adverse effect of nitroglycerin and other nitrates, 
occurring in 30-60% of patients receiving nitrate therapy with long acting agents [13]. In 
addition, nitroglycerin can increase ventilation-perfusion mismatch and thereby exacerbate 
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hypoxemia. The most worrisome side effect is unintentional systemic hypotension leading 
to reflex tachycardia and aggravation of an already ischemic myocardium. Patients with 
inferior wall MI, frequently associated with RV infarction, are reliant on RV preload for 
adequate cardiac output and would be especially susceptible to extreme hypotension from 
nitroglycerin. Should bradycardia and hypotension result from nitroglycerin use, one 
should discontinue the drug, elevate the patient’s legs, rapidly provide fluids and 
administer atropine. 
The greatest limitation to nitrate therapy is the tolerance that the body develops 
to its anti-ischemic actions with continued use. The body rapidly loses sensitivity to the 
actions of nitrates and requires a drug-free interval in order to restore previous sensitivity. 
The reason for tolerance is not certain although several etiologies have been proposed. 
One possibility is that the body depletes certain sulfhydryl groups required to convert 
organic nitrates to nitric oxide. A recent suggestion is that increased production of 
superoxides by the vasculature may be responsible. Continuous infusion of intravenous 
nitroglycerin for 24-48 hours following acute MI should not cause tolerance. If tolerance is 
evident, the dose can be increased [1]. Nitroglycerin patches, in contrast, are worn for 12 
hours and removed for 12 hours [13]. 
An important drug interaction to be aware of is the decreased sensitivity to heparin 
that occurs when one is taking nitroglycerin and heparin simultaneously. This is important 
to recognize, as one might require an increased dose of heparin to maintain effectiveness if 
nitroglycerin is also administered. Likewise, the patient is at a greater risk of bleeding from 
the heparin dose when nitroglycerin is discontinued. 
c. Overview of Clinical Trials 
In addition to its anti-ischemic effects, experimental and clinical evidence suggests 
that nitroglycerin will also limit infarct size, improve function in the infarcted region, and 
decrease LV remodeling that may occur following a Q-wave MI. An improvement in 
mortality and cardiac morbidity following prompt IV nitroglycerin use has also been shown 
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[1]. A meta analysis indicated that nitroglycerin decreased the odds of mortality from acute 
MI by 35% (95% Cl, 28-49%; p<0.001) [22]. 
The GISSI-3 trial [23] and the ISIS-4 trial [24] are two large trials that examined the 
effects of nitrates in the context of thrombolytic and aspirin therapy with a primary end 
point of short-term mortality. In these trials and when all data are compiled from the 
various randomized controlled trials involving nitrate therapy in AMI, there is a small, 
statistically significant relative reduction in mortality (5.5%+/-2.6%; p=0.03) which 
corresponds to saving about 4 lives for every 1000 persons treated. 
d. Summary 
In summary, nitroglycerin is the drug of choice for periodic ischemic pain and is 
effective at decreasing blood pressure and alleviating pulmonary congestion. Although 
there is no definitive data, a patient with an AMI and without bradycardia, excessive 
tachycardia, or hypotension should be treated with intravenous nitroglycerin for the first 
24-48 hours after hospitalization. Intravenous infusion enables a rapid onset of action, 
easy dosing control with frequent heart rate and cuff blood pressure measurement, and the 
ability to quickly end treatment rapidly should unwanted effects occur. Intravenous 
nitroglycerin should also be administered to manage patients with CHF or hypertension. 
Patients with CHF and large Q-wave infarcts should continue treatment with oral or topical 
preparations. However, since no increase in outcome was observed in the ISIS-4 or 
GISSI-3 trials, when over 70,000 patients were followed on nitrates versus placebo, or 
when all relevant randomized controlled trials are analyzed together, it is clear that routine 




2. Aspirin and Other Platelet-Active Drugs 
a. Mechanism of Action 
Since platelets and thrombus formation are key factors in pathogenesis of ischemia 
and infarction, antiplatelet agents should, intuitively play a crucial role in medical 
management of occlusive cardiovascular disease. 
Aspirin is a weak organic acid that irreversibly acetylates, and thus inactivates, 
cyclooxygenase. Since cyclooxygenase is a key enzyme in the synthesis of prostaglandin 
and thromboxane A2 from arachiodonic acid, aspirin can irreversibly inhibit thromboxane 
synthesis in platelets. The inhibition is permanent for the 7-10 day life time of the platelet, 
as platelets lack a nucleus and thus cannot synthesize new cyclooxygenase. Being that 
thromboxane A2 is necessary to induce platelet aggregation, aspirin treatment irreversibly 
suppresses platelet aggregation, the initial step in thrombus formation [13]. Aspirin will 
also affect platelets through its actions on vascular endothelial cells. In these cells aspirin 
inhibits the production of prostacyclin, an inhibitor of platelet aggregation. This effect, 
however, is short-lived as vascular endothelial cells do contain nuclei and can generate new 
cyclooxygenase in response to aspirin therapy. 
b. Prevention of Thrombotic Complications of Atherosclerosis 
The Antiplatelet Trialists’ Collaboration, which included 145 trials using antiplatelet 
therapy (mostly aspirin), revealed that antiplatelet therapy is effective in preventing vascular 
events in patients with AMI, history of MI, history of stroke or cerebral ischemia, unstable 
angina, and other vascular diseases. All together, nonfatal MI, nonfatal stroke, and 
vascular death were reduced by 30%, 30%, and 17%, respectively, in high-risk patients. 
Aspirin has been found to be more beneficial in patients with a vascular history, preventing 
35 and 40 events per 1000 treated patients with a history of infarction or stroke, and 
preventing 4 events per 1000 asymptomatic men treated. 
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c. Side Effects 
When aspirin is used as secondary prevention in patients with coronary artery 
disease, it clearly reduces the risk of stoke. However, when studied in primary prevention 
trials, in patients without atherosclerotic disease, aspirin is associated with a small raise in 
stroke rates. It is speculated that perhaps its antihemostatic effect, which may slightly 
increase the healthy patient’s risk of cerebral hemorrhage, is offset in the patient with 
coronary artery disease by its beneficial decrease of thromboembolic stroke [1]. 
The other main adverse effects of aspirin relate to its gastrointestinal actions. As 
mentioned previously, aspirin blocks the production of prostaglandins and thromboxane 
A2. In the gastrointestinal system, however, these prostaglandins play an important, 
protective role; prostacyclin (PGI2) inhibits production of gastric acid while PGE2 and 
PGF2 alpha stimulate the production of mucus that protects the lining of the stomach and 
small intestine. When aspirin is ingested and these prostanoids are not synthesized, there is 
an increase in gastric acid secretion and a decrease in mucous protection, predisposing the 
patient to epigastric pain, ulceration, and/or hemorrhage [13]. These side effects can be 
limited by diluting the aspirin solution, using enteric coated aspirin or treating the patient 
with cimetidine or antacids. Rectal suppositories can be used in the patient with a bleeding 
history from peptic ulcers. 
Aspirin should not be used in patients with known hypersensitivity and should be 
prudently administered to the patient with blood dyscrasia or liver failure. Another harmful 
effect associated with aspirin use is bleeding from surgical cuts [1]. In the Veterans 
Administration Cooperative Study [25], 6.5% of patients given aspirin and 1.7% of 
patients not receiving aspirin (Pc.Ol) had significantly greater post-operative chest drainage 
and further surgery because of hemorrhage. Other studies have similarly found an 
increased amount of post-operative chest drainage in patients that had been on aspirin, but 
did not find an association with the need for reoperation [26,27]. A solution found in 
another Veterans Administration Cooperative Study [28] is that if patients begin aspirin 
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therapy 6 hours after surgery, as opposed to prior to surgery, its anti-thrombotic effects on 
the saphenous vein bypass graft are still intact, and yet it is not associated with increased 
bleeding from surgical sites. 
d. Ticlopidine 
Ticlopidine inhibits platelet aggregation, as does aspirin, but uses a distinct 
mechanism. This drug targets the ADP pathway involved in platelet binding to fibrinogen 
and to each other. Part of its action involves blocking the GPIIb/IHa glyocoprotein 
receptor on the platelet membrane that binds fibrinogen. This drug is not used for 
emergency anti-platelet activity, as its onset of action begins 24-48 hours after 
administration. 
This agent has been found to decrease the incidence of thrombotic stroke and reduce 
the occurrence of AMI in patients with vascular pathology. A serious adverse effect of 
ticlopidine therapy, however, is neutropenia which is reversible and has occurred following 
treatment of greater than 2 weeks. Hence, ticlopidine administration is reserved for patients 
with cerebral ischemia who cannot tolerate aspirin, have been treated unsuccessfully with 
aspirin, or have contraindications to its use [1,13]. 
3. Antithrombotics/Anticoagulants 
a. Coagulation System 
The coagulation system is essentially a pathway of conversions of proenzymes to enzymes, 
finishing off in the polymerization of fibrinogen to fibrin. The intrinsic and extrinsic parts 
of the clotting cascade converge with the activation of factor X. Activated factors X and V 
and phospholipid are then necessary for the conversion of prothrombin to thrombin and 
thrombin is then essential for the ultimate conversion of fibrinogen to fibrin. There are 
many control mechanisms to avoid the unchecked spread of coagulation. In the presence of 
fibrinogen and fibronectin, thrombin induces the endothelial cell to liberate urokinase and 
tissue-type plasminogen activators (tPA) to convert plasminogen to plasmin, an enzyme 
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which solubilizes fibrin and dissolves blood clots. Among the several other mechanisms of 
checks and balances used by the body to control coagulation is the role of antithrombin III. 
This molecule, in the presence of heparin-like molecules on endothelial cells inhibits 
thrombin and reduces the activity of factors Xlla, Xia, Xa, and IXa- essential enzymes of 
the intrinsic pathway [29]. 
One therapeutic angle in preventing thrombus formation is to target thrombin and 
thereby inhibit fibrin formation from fibrinogen. Not only is thrombin a key component of 
initial thrombus formation, but it also is important in activating platelets. Additionally, 
upon exposure to the circulating blood, active thrombin that is bound to a developing clot 
will further convert fibrinogen to fibrin. Hence, inhibiting the action of thrombin is a 
potent way to curb clot formation. 
b. Heparin 
1. Mechanism of Action 
The pharmacologic agent heparin, first described in 1916, is a mixture of straight- 
chain anionic glycosaminoglycans of different sizes, with molecular weights ranging 
between 5000 to 20000. The different sized molecules exert distinct effects on the 
coagulation system, overall leading to a rapid anticoagulant effect with maximal 
anticoagulation taking place within minutes after intravenous injection of heparin. Heparin 
binds to antithrombin III causing a conformational change that enables antithrombin III to 
combine with and inactivate thrombin that is not already bound to fibrin6. Additionally, the 
heparin-AT-III complex can inactivate activated factor X. 
The effect of a heparin dose on the coagulation system can be adjusted in several 
ways, including the specific combination of heparin molecules administered, blood levels 
of AT-III, plasma levels of proteins that inactivate thrombin such as platelet factor IV, and 
the capability of heparin to effect thrombin bound to clot. 
6 The complex of heparin and AT-III is considerably large and generally not effective against thrombin 
bound to clot. 
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2. Overview of clinical trials 
In this age of aspirin, beta-blockers, nitrates and ACE inhibitors, there are few 
studies that have formally evaluated the efficacy of heparin among patients not receiving 
thrombolytic therapy. However, there are useful data from studies performed before the 
emergence of thrombolytic therapy which serve as the basis for the recommendation to 
administer heparin to patients not receiving thrombolytic therapy. In these trials the control 
groups were not treated with the routine therapies of today, such as aspirin [1]. An 
overview of these studies reveals that a 17% decrease in mortality and a 22% decrease in 
reinfarction risk occurred when heparin was administered [30]. 
Recommendations for heparin therapy in patients receiving thrombolytic therapy 
depend on the type of thrombolytic used. Thrombolytic agents that are nonspecific such as 
streptokinase, anistreplase, and urikinase require less additional anticoagulation. For, these 
agents cause an overall disruption of the coagulation system, including consuming factors 
V and VIII and engendering vast amounts of fibrin degradation products, which themselves 
serve as anticoagulants. In contrast, agents such as alteplase and reteplase may not produce 
many fibrinogen degradation products or consume many coagulation factors. These agents 
would require greater anticoagulation effects from heparin. 
Overall, clinical trials do not support the use of intravenous heparin with a 
nonspecific thrombolytic versus subcutaneous heparin with the thrombolytic. Additionally 
it is unclear whether subcutaneous heparin is beneficial. 
Heparin is, however, clearly recommended in the patient with a high risk for 
embolic stroke7. Empirical evidence suggests that early heparin administration to the MI 
patient will reduce the likelihood of systemic emboli [1]. In the SCATI trial [31] patients 
randomly assigned to heparin therapy showed an in-patient mortality of 4.6% compared to 
7 This group of patients includes those with AF, a prior history of embolism, echocardiographic evidence 
of a left ventricluar thrombus and a large, anterior MI. 
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8.85% in the placebo treated group along with a decrease in stroke rate in the heparin- 
treated group. 
3. Recommendations [1]: 
Class I 
1. Patients undergoing percutaneous or surgical revascularization 
Class Ila 
1. Intravenously in patients undergoing reperfusion therapy with alteplase. 
2. Subcutaneously (7500 U twice daily) (intravenous heparin is an 
acceptable alternative) in all patients not treated with thrombolytic therapy 
who do not have a contraindication to heparin. In patients who are at high 
risk for systemic emboli (large or anterior MI, AF, previous embolus, or 
known LV thrombus), intravenous heparin is preferred. 
3. Intravenously in patients treated with nonselective thrombolytic agents 
(streptokinase, antistreplase, urokinase) who are at high risk for systemic 
emboli (large or anterior MI, AF, previous embolus, or known LV 
thrombus). 
Class lib 
1. Patients treated with nonselective thrombolytic agents, not at high risk, 
subcutaneous heparin, 7500 U to 12500 U twice a day until completely 
ambulatory 
Class III 
1.Routine intravenous heparin within 6 hours to patients receiving a 
nonselective fibrinolytic agent (streptokinase, anistreplase, urokinase) who 
are not at high risk for systemic embolism. 
4. Antiarrhythmic drugs 
a. Introduction to Arrhythmia 
Arrhythmia is a frequent problem in post-infarction patients, occurring in over 80% 
of patients with AMI. Approximately 5% of hospitalized patients post AMI will develop 
ventricular fibrillation, as cardiac output is impaired and tachycardia may deteriorate into 
ventricular fibrillation. Of these episodes, 80% occur in the first 12-24 hours [5]. 
Cardiac arrhythmias consist of depolarizations that result from disturbances in 
impulse formation, disturbances in impulse conduction or both [13]. These aberrant 
impulses have a site of origin, rate, regularity, or conduction that is abnormal. 
Arrhythmias can cause contractions that are too rapid, too slow or asynchronous and thus 
provide inadequate cardiac output. More serious, even lethal rhythm disturbances may 




b. General Mechanism of Antiarrhvthmic Therapy 
Since arrhythmias result from aberrant pacemaker activity or deviant impulse propagation, 
the goal of antiarrhythmic therapy is to limit ectopic pacemaker activity and change 
conduction or refractoriness in reentrant circuits to impair circus movements. The primary 
methods by which this can be accomplished include targeting the action potential of 
myocytes by blocking sodium channels, blocking sympathetic autonomic effects in the 
heart, prolonging the effective refractory period, or blocking calcium channels. 
Antiarrhythmic drugs have greater effects on abnormal tissue than normal tissue. 
They will decrease the automaticity of ectopic pacemakers more than that of the sinoatrial 
node. Also, they reduce conduction and excitability and increase refractory period to a 
greater extent in depolarized tissue than in normally polarized tissue, mainly by selectively 
blocking the sodium or calcium channels of depolarized cells. 
c. Adverse Effects 
In patients with arrhythmias treatment with antiarrhythmic dmgs can save the 
patient’s life. In other instances, however, the hazards of antiarrhythmic therapy which 
include inducing lethal arrhythmias in certain instances, may outweigh the potential benefits 
of treatment [32]. Examples of dmgs that are beneficial to use and result in decreased 
morbidity include the use of lidocaine to terminate ventricular tachycardia or adenosine or 
verapamil for supraventricular tachycardia [13]. In contrast, many other agents are known 
to be proarrhythmic and would not be useful [32]. 
The Cardiac Arrhythmia Suppression Trial (CAST) showed that the two class IC 
antiarrhythmic dmgs, encainide and flecainide, did prevent ectopic ventricular beats in post 
MI patients. However, if either dmg continued to be used, a two- to three-fold increase in 
death due to arrhythmias resulted. Unexpectedly, this trial challenges the seemingly logical 
thought that treating post-infarction arrhythmias, or any arrhythmia in general, is beneficial, 
causing physicians to be more skeptical in the use of antiarrhythmics [13]. In general, it is 
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now established that due to the proarrhythmic risk of antiarrhythmic therapy, asymptomatic 
or minimally symptomatic arrhythmias should not be treated. 
d. Specific Agents and Recommendations 
1. Lidocaine 
Lidocaine is both an antiarrhythmic and local anesthetic that targets sodium channels 
with relatively rapid onset [1]. Randomized studies revealed that lidocaine decreases risk 
of primary VF in both the prehospital and early hospital environment [33, 34]. 
Nevertheless, deaths relating to asystole and electromechanical dissociation occur, resulting 
in no overall mortality decrease. 
Following AMI, treatment is advised for premature ventricular complexes, VT or 
VF. In this setting, lidocaine is the drug of choice. Except for patients in shock, it is well 
sustained [l]. According to the 1996 ACLS protocol [35], lidocaine is the first 
antiarrhythmic agent to be administered to patients who have had a cardiac arrest with 
persistent VT/VF even after defibrillation and epinephrine. It is also recommended for 
cardiac arrest patients to ward off recurrence, as therapy for unsustained ventricular ectopy, 
and as treatment for wide complex tachycardia of undetermined type. 
2. Bretvlium 
Bretylium is a quaternary ammonium compound that has been shown, clinically and 
experimentally , to have strong antifibrillatory but weak antiarrhythmic effects. It is used to 
treat resistant VT and VT in the hemodynamically unstable patient. It is recommended in 
the ACLS protocol to be used after lidocaine and previous steps have been unsuccessful 
against VF or pulseless VT or when VF recurs despite epinephrine and lidocaine use. In 
patients with VT and with a pulse, it is used only once treatments with lidocaine and 
procainamide have been attempted. 
3. Procainamide 
Procainamide is an antiarrhythmic that works on sodium channels and also has local 
anesthetic properties. It is used as a secondary agent in life threatening ventricular 
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arrhythmias. When therapy is needed to suppress premature ventricular complexes and 
recurrent VT, after lidocaine use has either failed or is contraindicated, procainamide can be 
administered. It can also be used as a secondary agent for wide complex tachycardias of 
undetermined type. According to ACLS guidelines, procainamide should be considered 
after defibrillation, epinephrine, lidocaine, bretylium, and magnesium have failed to treat 
VF and VT without a pulse. Side effects of procainamide use involve arrhythmias 
including torsades de pointes. Renal failure patients may accumulate metabolites and be at 
higher risk for torsades [1]. 
4, Beta-adrenoceptor Blockers 
Traditionally, beta-blockers, class II antiarrhythmic agents, have been considered 
relatively poor agents for the treatment of ventricular arrhythmias. However, recently 
there has been convincing evidence that beta-blockers have important antiarrhythmic 
actions, serving to prevent arrhythmic and sudden death. Specifically, B blockade may 
prevent sudden death and VF, but is less effective against spontaneous ectopy or 
spontaneous or inducible monomorphic VT. The antiarrhythmic effects of beta-blockade 
may be due to an intrinsic action of these drugs, an affect on the central nervous system, 
and preservation of the antiarrhythmic action of other agents amidst sympathetic 
stimulation. 
A specific role for beta-blockade in antiarrhythmic therapy is still evolving. Recent 
studies do show that agents with class III effects and beta-blockade are superior to class I 
or purely class II agents in treating high-risk populations. Although still unproved, beta- 
blockade is a reasonable therapy for patients who have not had cardiopulmonary arrest and 
are at high risk for VF. Beta-blockade, alone, in treatment of patients who have suffered a 
cardiopulmonary arrest or who have sustained VT is unproved, but possibly beneficial. 
Overall, beta-blockers have the greatest effect on survival in patients with decreased left 
ventricular function and treatment that involves the use of this class of dmgs should be 




Amiodarone is an antiarrhythmic with a vast, complex array of actions. 
Intravenous amiodarone is appropriate for prophylaxis against and treatment of recurring 
VF and hemodynamically destabilizing VT. Long term therapy with oral amiodarone can 
be used if the intravenous dose is effective. Studies have shown the time to first VT/VF 
recurrence in patients treated with amiodarone is dose-dependent, although mortality is not 
[37]. This drug is equal to bretylium in effectiveness against VT/VF recurrence but is better 
tolerated [38]. 
e. Summary 
Prophylactic antiarrhythmic therapy in the first 24 hours after acute MI is not 
recommended. Although lidocaine prophylaxis can prevent arrhythmias in AMI patients, it 
does not decrease mortality and does increase risk for asystole. Thus, this approach is only 
advised in patients with frequent ectopy or unsustained ventricular tachycardia. Although 
intravenous magnesium sulfate proved useful in one study, ISIS-4 did not find routine 
magnesium administration advantageous. Nonetheless, atropine, lidocaine, a transvenous 
pacemaker or transcutaneous pacing patches, a defibrillator and epinephrine should be 
directly accessible for the post AMI patient [1,5]. 
The treatment of a patient with arrhythmia following AMI is situation dependent. 
Extensive left ventricular systolic dysfunction is frequently the cause of atrial fibrillation in 
the post- MI patients. Should this cause persistent ischemia or compromise the patient’s 
hemodynamic function, direct-current cardioversion is recommended. However, if these 
comorbidities are not present, beta-blockers or digitalis should be used to slow the 
arrhythmia. Ventricular fibrillation or monomorphic ventricular tachycardia along with 
chest pain, hypotension or pulmonary congestion should be treated with direct-current 
countershock. Monomorphic ventricular tachycardia that is not associated with angina, 
hypotension or pulmonary congestion should receive antiarrhythmic therapy- intravenous 
lidocaine, procainamide or amiodarone. 
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In general, post AMI patients should only receive both acute or long term 
antiarrhythmic therapy (except beta-blockers) for life-threatening arrhythmias or those with 
extensive symptoms. Antiarrhythmic therapy is not appropriate for risk reduction in 
response to arrhythmias that are not life-threatening [1]. 
5. Beta-Adrenoceptor Blocking Agents 
a. General Considerations 
All the clinically approved beta-blockers are competitive antagonists of 
catecholamines and other beta agonists at beta-adrenoceptors. Nonselective beta-blockers 
bind to both beta-1 and beta-2 receptors , whereas cardioselective beta-blockers principally 
bind at beta-1 receptors. These drugs also vary in intrinsic sympathomimetic activity, 
central nervous system (CNS) effects, and in pharmacokinetics. Although all beta-blockers 
reduce blood pressure in hypertension, they do not prompt postural hypotension, as the 
alpha-adrenoceptors are not antagonized and still maintain usual sympathetic control of the 
vasculature. Beta-blockers are also beneficial in managing angina, cardiac arrhythmias, 
MI, and glaucoma, as well as helping to prophylax against migraine headaches. 
b. Coronary Effects 
In general, beta-blockers have prominent effects on the heart. As one might expect 
from the role of adrenoceptors in cardiac regulation, antagonism of the receptors by beta- 
blockers will have negative chronotropic and inotropic effects, resulting in a decrease in 
cardiac output. They directly lower sino-auricular and atrioventricular activity, decreasing 
heart rate. The resulting bradycardia is generally dose-limiting [13]. Slowed conduction 
through the atrioventricular node and an increased PR interval is a result of adrenoreceptor 
blockade in the atrioventricular node. Cardiac output, work, and oxygen consumption are 
decreased by blockade of beta-1 receptors, useful effects in the treatment of angina. The 
beta-blockers are successful in attenuating supraventricular cardiac arrhythmias but are 
generally not beneficial against ventricular arrhythmias (beside those prompted by 
exercise). Additionally, beta-blockers oppose the release of renin stimulated by the 
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sympathetic nervous system. This may in part be responsible for its lowering effects on 
blood pressure [13, 32]. 
Beta blockers have a protective effect on the myocardium. Thus, prophylaxis with 
beta-blockers will protect patients with a history of myocardial infarction from experiencing 
another infarct. In addition, beta-blocker administration immediately following an MI will 
decrease infarct size and quicken recovery . One potential mechanism may be the blocking 
of the effects of circulating catecholamines, which would augment oxygen demand in an 
already ischemic heart muscle. Certain beta-blockers like propanolol also reduce the 
incidence of sudden arrhythmia after myocardial infarction [13]. 
c. Adverse Effects 
While the above effects are beneficial in some, they are hazardous to others and 
thus should not be used in those with contraindications. Bronchoconstriction, arrhythmias, 
sexual impairment, disturbance in metabolism and drug interactions are common side 
effects of beta-blocker use. Central nervous system effects include sleep disturbances, 
sedation, and depression. The respiratory effects are important to consider in the 
asthmatic patient, as nonselective beta-blockers can worsen asthma or other forms of 
airway obstruction causing a once trivial condition to be a severe handicap. Additionally, 
since beta-blockers lower the sympathetic drive of the heart, patients with abnormal 
myocardial function may decompensate from beta-blocker therapy and may not be able to 
handle the ensuing decrease in myocardial contractility and excitability [13,32]. 
d. Overview of Clinical Trials 
Beta-blockers have been shown to decrease morbidity and mortality in post MI 
patients whether they are taken in the early hours of infarction or weeks, months, or years 
later as a form of secondary prevention. 
Beta-blockers administered to a patient in the beginning hours of infarction can 
decrease the size of infarction and concomitant complications in the patient not receiving 
thrombolytic therapy as well as decrease the rate of infarction in the patient who is 
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receiving thrombolysis. In the early hours of infarction, beta-blockers act to decrease the 
work of the heart by lowering heart rate, systemic arterial pressure and contractility, 
thereby reducing myocardial oxygen demand. The decrease in heart rate caused by beta- 
receptor blockade, extends the time of diastole and allows greater opportunity for 
myocardial perfusion. This effect especially increases blood flow to the subendocardium. 
Overall, these actions lead to the great benefits described above for the AMI patient [1]. 
In patients who are not receiving thrombolytic therapy, intravenous beta-blockers 
will not only limit infarct size but will also decrease short-term mortality. These results 
were evident by the First International Study of Infarct Survival [39]. In this study over 
16,000 patients were enrolled within 12 hours of onset of suspected MI symptoms. 
Patients were immediately given 5-10 mg of intravenous atenolol followed by 100 mg of 
oral atenolol each day. After 7 days, mortality was reduced from 4.3% to 3.7% (Pc.02) . 
This corresponds to 6 lives saved per 1000 treated. The decrease in mortality seen in the 
atenolol patients was apparent from day 1 onward. Similar results were found in the 
Metoprolol in Acute Myocardial Infarction (MIAMI) trial [40]. 
Beta-blockers given together with thrombolytic therapy will decrease the chance of 
ensuing nonfatal reinfarction and recurrent ischemia in AMI patients. Additionally, if 
given within 2 hours of symptom onset, the beta-blockers can reduce mortality in these 
patients. These results were shown in the TIMI-II trial [41]. 
If untoward side-effects such as AV block, extreme bradycardia, or hypotension 
should occur from beta-blocker therapy, the predicament can be rapidly reversed with 
administration of a beta-adrenergic agonist such as 1-5 micro grams of isoproterenol [1]. 
e. Recommendations for Early Therapy [1]: 
Class I 
1. Patients without a contraindication to beta-adrenoceptor blocker 
therapy who can be treated within 12 hours of onset of infarction, 
irrespective of administration of concomitant thrombolytic therapy. 
2. Patients with continuing or recurrent ischemic pain. 





1. Non-Q wave MI 
Class III 
1. Patients with moderate or severe LV failure or other 
contraindications to beta-adrenoceptor blocker therapy. 
f. Contraindications 
The AHA/ACC lists the following relative contraindications to beta-blocker therapy 
[1]: 
heart rate less than 60 bpm; systolic arterial pressure less than 100 mm HG; 
moderate or severe LV failure; signs of peripheral hypoperfusion; PR interval 
greater than 0.24 second; Second or third degree AV block; severe chronic 
obstructive pulmonary disease; history of asthma; severe peripheral vascular 
disease; insulin-dependent diabetes mellitus. 
g. Summary 
In summary, all patients with evolving AMI and without contraindications, whether 
they receive thrombolytic therapy or not, should receive intravenous beta-blockers as soon 
as possible followed by oral therapy. This therapy has been shown to reduce morbidity 
and mortality in these patients [1]. 
6. Angiotensin Converting Enzyme Inhibitors 
a. General considerations 
ACE inhibitors block the enzyme peptidyl dipeptidase that hydrolyzes angiotensin I 
to form the potent vasoconstrictor, angiotensin II. They also decrease the rate of 
bradykinin inactivation by inhibiting the plasma kininase that inactivates bradykinin, a 
potent vasodilator. Vasodilation occurs as a result of the combined effects of less 
vasoconstriction due to lower levels of angiotensin II and the potent vasodilating effect of 
increased bradykinin. Since these agents lower the levels of circulating angiotensin II, 




b. Coronary Effects 
ACE inhibitors reduce vascular resistance, venous tone, and blood pressure causing 
an increase in cardiac output. These agents also hamper the usual angiotensin II-mediated 
rise in epinephrine and aldosterone that occurs in CHF. ACE inhibitors also add to the 
beneficial effects seen in patients who are also receiving a diuretic and/or digoxin. Both 
morbidity and mortality have substantially decreased from the application of ACE 
inhibitors among patients with CHF. Therapy with ACE inhibitors has also lessened 
arrhythmic death, myocardial infarction and strokes [13]. 
c. Adverse effects 
In patients who are hypovolemic, severe hypertension can occur with the first doses 
of ACE inhibitors. Other adverse effects include acute renal failure, especially in patients 
with bilateral renal artery stenosis (or stenosis of the renal artery of a solitary kidney), 
hyperkalemia, angioedema, and a persistent dry cough, sometimes accompanied by 
wheezing. ACE inhibitors should not be used in the second or third trimesters of 
pregnancy [32]. 
d. Overview of Clinical Trials 
A series of trials (ISIS-4 [24], GISSI-3 [23], SMILE [42], SAVE [43], AIRE [44], 
TRACE) have shown that ACE inhibitor treatment can increase both short- and long-term 
survival in AMI patients. The patients that benefit most and the only ones that should 
maintain chronic ACE inhibitor therapy are those patients with low ejection fractions, large 
infarctions, or clinical evidence of heart failure [5]. 
Although all trials in which early oral ACE inhibitors are used in post-infarct 
patients display a gain from treatment, preliminary data from the ISIS-4 and GISSI-3 trials 
suggest that ACE inhibitors have greater benefit in patients with anterior infarct or high risk 
patients with previous infarction, heart failure, and tachycardia. From these studies it is 
recommended that ACE inhibitor treatment be started in the first 24 hours, preferably after 
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thrombolysis and once the blood pressure is stable. After 4-6 weeks, if there are no 
complications and no evidence of LV dysfunction, treatment can be terminated. 
Treatment with ACE inhibitors is not advised if systolic blood pressure is less than 
100, if there is renal failure or a history of bilateral renal artery stenosis, or if the patient is 
allergic to ACE inhibitors. Therapy should begin with low oral doses and escalate slowly 
to a complete dose in 24-48 hours. Intravenous enalaprilat should not be administered [1]. 
e. Recommendations [1]: 
Class I 
1. Patients within the first 24 hours of a suspected acute MI with 
ST-segment elevation in two or more anterior precordial leads or with 
clinical heart failure in the absence of significant hypotension or known 
contraindications to use of ACE inhibitors. 
2. Patients with MI and LV ejection fraction less than 40% or 
patients with clinical heart failure on the basis of systolic pump dysfunction 
during and after convalescence from acute MI. 
Class Ha 
1. All other patients within the first 24 hours of a suspected or 
established acute MI, provided significant hypotension or other clear-cut 
contraindications are absent. 
2. Asymptomatic patients with mildly impaired LV function (ejection 
fraction 40% to 50%) and a history of old MI. 
Class lib 
1. Patients who have recently recovered from MI but have normal or 
mildly abnormal global LV function. 
f. Summary 
In summary, an oral ACE inhibitor should be administered within hours of 
hospitalization in the patient with evolving MI with ST segment elevation or LBBB, 
supposing the patient does not have hypotension and no other contraindications exist. 
Following initial treatment, the patient with LV systolic dysfunction (ejection fraction 
below 40%) or clinical CHE should continue treatment indefinitely. However, ACE 
inhibitors can be terminated by 6 weeks in patients without impaired LV systolic function 
and without complications [1]. 

37 
7. Calcium Channel Blockers 
a. General Considerations 
The calcium channel blockers are divided into three chemical classes, each with different 
pharmacokinetics and clinical indications. Nifedipine is the prototype of the 
dihydropyridine family, verapamil represents the diphenylalkylamines and diltiazem is a 
benzothiazepine. One can understand the role of these drugs by identifying the crucial role 
that intracellular calcium plays in sustaining smooth-muscle tone and in contracting the 
myocardium. Calcium reaches muscle cells through specific voltage-sensitive calcium 
channels. Influx triggers release of calcium from the sarcoplasmic reticulum and 
mitochondria, further augmenting the cytosolic calcium concentration. Calcium channel 
antagonists attach to L-type calcium channels in the heart and in smooth-muscle of the 
coronary and peripheral vasculature, preventing the influx of calcium. This results in 
vascular smooth muscle relaxation, primarily dilating arterioles [13]. 
b. Coronary Effects 
Cardiac muscle relies highly on calcium influx for normal function. The “slow- 
response” or calcium-dependent action potentials—causing impulse generation in the 
sinoatrial node and conduction in the atrioventricular node— may be limited or blocked by 
all of the calcium channel blockers. In a dose-dependent fashion, these drugs also decrease 
cardiac contractility and cardiac output, as excitation-contraction coupling in all cardiac cells 
is also dependent on calcium flow. Reducing this mechanical function is one of several 
ways that calcium channel blockers decrease myocardial oxygen demand. 
It has been found experimentally that ischemia causes membrane depolarization and 
subsequent calcium influx. Elevated intracellular calcium in these ischemic cells activates 
several ATP-consuming enzymes, further depleting the already minimal cellular energy 
stores and further increasing myocardial susceptibility to ischemic damage. In experimental 
animals, the calcium channel blockers have been shown to protect against the detrimental 
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affects of calcium influx by lowering the chance of arrhythmias and decreasing the final 
size of evolving infarctions [32]. 
c. Adverse Effects 
The harmful effects of calcium channel blockers are rare and include direct 
extension of their therapeutic actions. If calcium influx is inhibited to an extreme, severe 
cardiac depression, including cardiac arrest, atrioventricular block, bradycardia, and 
congestive heart failure can ensue. Concomitant use of beta-blockers causes increases 
sensitivity to the cardiodepressant effect of calcium channel blockers. Although infrequent, 
minor side effects include constipation in 10% of patients, nausea, dizziness, flushing, 
edema, gingival hyperplasia, headache, and a feeling of fatigue caused by a decrease in 
blood pressure [13, 32] . 
d. Specific agents and overview of clinical trials 
1. Nifedipine 
Numerous clinical trials, including The Nifedipine Angina Myocardial Infarction 
Study (NAMIS) [45], the Norwegian Nifedipine Multicenter Trial [46], the Trial of Early 
Nifedipine Treatment in Acute Myocardial Infarction (TRENT) [47], and the Secondary 
Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) [48,49] ,have been performed 
with first-generation, nonsustained-release nifedipine to assess the benefit of this calcium 
channel blocker among patients with AMI. Results from these studies indicate that 
Nifedipine does not reduce the incidence of reinfarction or mortality whether it is given to 
patients within 24 hours of acute MI or later. This rule applies to patients regardless of 
gender, risk level and type of MI, and irrespective of simultaneous use of beta-blockers or 
thrombolysis. In fact, this form of nifedipine can be harmful in patients with tachycardia or 
hypotension as it can decrease the necessary perfusion pressure to the heart, cause the 
arteries adjacent to the infarct-area to dilate disproportionately (thus “stealing” blood from 
the infarct area), and can cause a reflex sympathetic activation increasing the oxygen 




The results found from studies with immediate-release verapamil differ somewhat 
from the nifedipine trials. While no overall decrease in mortality was found when 
verapamil was administered to patients post AMI, a reduction in the combined outcome of 
reinfarction or death was seen when this drug was administered several days after AMI in 
patients who were not suitable to receive B-adrenoceptor blocking agents. This subgroup 
of patients must also have intact LV function without clinical evidence of heart failure. If 
however, the patient has heart failure of bradyarrhythmias within the first 1-2 days after 
AMI, verapamil administration could be damaging [1]. In one study which randomized 
1700 patients under the age of 75 there was a 16.7% reduction in 18 month death or MI 
when verapamil was administered within 2 weeks of MI [50]. 
3. Diltiazem 
The analysis of two studies, the Muticenter Diltiazem Postinfarction Trial (MDPIT) 
[51] and the Diltiazem Reinfarction Study (DRS) [52-55] indicates that immediate-release 
diltiazem (begun 3-15 days after MI in the former study and 24-72 hours after MI in the 
latter study) will benefit patients who have intact LV function and no heart failure if taken 
following a Q- wave or non Q- wave infarction. However, in patients with LV 
dysfunction, diltiazem, like the other calcium channel blockers, is harmful. It is difficult to 
assess how beneficial diltiazem would be in the treatment of AMI today, as both MDPIT 
and DRS were conducted in an era prior to the popularity of aspirin use for coronary 
ischemia. Additionally, the results of MDPIT may be confounded by the use of b-blockers 
in 53% of the placebo and 55% diltiazem-treated patients [1]. 




1. Verapamil or diltiazem may be given to patients in whom B- 
adrenoceptor blockers are ineffective or contraindicated (i.e., 
bronchospastic disease ) for relief of ongoing ischemia or control of a rapid 
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ventricular response with AF after acute MI in the absence of CHF, LV 
dysfunction, or AV block. 
Class II b 
1. In non-ST-elevation infarction, diltiazem may be given to patients 
without LV dysfunction, pulmonary congestion, or CHF. It may be added 
to standard therapy after the first 24 hours and continued for 1 year. 
Class III 
1. Nifedipine (short acting) is generally contraindicated in routine 
treatment of acute MI because of its negative inotropic effects and the reflex 
sympathetic activation, tachycardia, and hypotension associated with its 
use. 
2. Diltiazem and verapamil are contraindicated in patents with acute 
MI and associated LV dysfunction or CHF. 
f. Summary 
There are no studies that support the use of calcium channel blockers in early 
therapy or secondary prevention for the vast majority of typical AMI patients. In fact, in 
certain patient populations with cardiovascular disease they seem to be harmful, as they can 
exacerbate ischemia and cause death from myocardial depression or reflex tachycardia. 
Diltiazem and verapamil may lower the chance of reinfarction in patients without ST- 
segment elevation or LBBB in whom pulmonary congestion is absent. However, it is not 
certain whether these drugs are advantageous beyond aspirin and beta-blocker therapy. 
Immediate-release, first-generation dihydropyridines such as nifedipine are contraindicated 
in the acute MI patient. There are no data to assess the utility of second-generation 
dihydropyridines in AMI management [1]. Hence, calcium channel blockers should be 
reserved as second- or third- line agents after nitrates and beta-blockers for treatment of 
hypertension or ischemia [5]. 
8. Inotropic Agents 
a. General Considerations 
Positive inotropic agents strengthen cardiac muscle contractility, and thus expand 
cardiac output. Despite their distinct mechanisms, each inotropic agent will elevate 




Three classes of inotropic agents can be described: those with predominant 
vasoconstrictive activities; catecholamines that mostly affect inotropy and have very little 
vasoconstrictive properties; and phosphodiesterase inhibitors which mainly have 
vasodilating properties. 
Dopamine and norepinephrine are the prototypes of the vasoconstrictor inotropic 
agents. Norepinephrine is essentially a vasoconstricting agent with positive inotropic 
effects. The exact actions of dopamine depend on dosage. At low doses it acts mainly on 
dopamine receptors to dilate the renal vasculature and on beta- adrenergic receptors to 
moderately increase contractility. If doses are increased, the beta-1 receptor activation 
dominates leading to positive chronotropic and inotropic effects. At still higher doses, 
dopamine leads to vasoconstriction as the alpha effects predominate. 
Dobutamine is the prototypical inotropic agent that is a catecholamine without 
vasoconstriction properties. It exerts positive inotropic effects by stimulating beta-1 
receptors. Amrinone and milrinone are phosphodiesterase inhibitors developed with the 
hope that they would improve cardiac output without predisposing to arrhythmias, as do 
the catecholamines. These agents both increase contractility and vasodilation, with a 
greater effect on preload than catecholamines. Long-term amrinone use has been associated 
with toxicity and long-term milrinone use with excessive mortality, and thus the use of 
these agents has not been as promising as was anticipated [1]. 
b. Digitalis 
1. General Considerations 
Since most of the cardiac glycosides are derived from the digitalis (foxglove) plant 
they are often referred to as digitalis or digitalis glycosides. Chemically alike, these 
compounds can all strengthen the contractility of the heart muscle, a “positive” inotropic 
action, and are therefore popular in treating heart failure. Like the antiarrhythmic drugs, the 
cardiac glycosides affect the flows of sodium and calcium ions in the cardiac muscle. 
These drugs have a low therapeutic index—they display only a small gap between a dose 
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that is therapeutically effective and one that is toxic or even lethal. The most popular agent 
among the digitalis glycosides is digoxin. 
2. Mode of Action 
The two main actions of digitalis responsible for its therapeutic effects include its 
regulation of cytosolic calcium concentration and increased contractility of the cardiac 
muscle. Cardiac glycosides inhibit the action of the sodium-potassium ATPase pump of 
the cardiac cell membrane. They reversibly bind to the pump causing an increase in the 
intracellular sodium concentration, favoring the transport of calcium into the cell via the 
sodium-calcium exchange mechanism. The increased levels of intracellular calcium 
increase the systolic force of contraction. 
The increased systolic force of contraction caused by digitalis glycosides is 
followed by several additional changes in cardiac physiology. Increased inotropy allows 
the cardiac output of the failing heart to more closely resemble that of the normal heart. 
This, in turn, results in a decrease in end-diastolic volume and an increased ejection 
fraction. This improvement in contraction efficiency results in improved circulation and a 
decrease in sympathetic activity. A decrease in peripheral resistance and slower heart rate 
follow. In addition, vagal tone is increased contributing to the decrease in heart rate. 
Overall, myocardial oxygen demand is lowered [13]. 
The electrical effects of digoxin on cardiac muscle lead to an early, short 
prolongation of the action potential, followed by a late period of shortening, especially of 
the plateau phase. This decrease in action potential duration is probably due to an influx of 
potassium caused by an increased amount of intracellular calcium. As a result of the 
shortened action potential, atrial and ventricular refractory periods are shortened as well. 
3. Adverse Effects 
“Digitalis toxicity” is one of the most frequently occurring adverse drug reactions. 
When the concentration of digitalis reaches toxic levels, the resting membrane potential 
becomes even more negative as a result of inhibition of the usual actions of the sodium- 
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potassium-ATPase pump. As toxicity continues, normal action potentials are followed by 
oscillatory depolarizing afterpotentials called “delayed afterdepolarizations.” These 
afterpotentials result from overloading the intracellular calcium stores and oscillations in the 
intracellular concentration of free calcium ion. These afterpotentials interfere with normal 
conduction in several ways. When below threshold, they cause the resting membrane 
potential to further decrease. If the afterpotential reaches threshold it will produce an action 
potential which forms a premature ventricular depolarization. Bigeminy will result on the 
EKG if the purkinje system regularly experiences these premature depolarizations. As 
toxicity progresses, these premature action potentials can elicit suprathreshold 
afterpotentials of their own. The result is a self-sustaining arrhythmia—ventricular 
tachycardia. With progression, this arrhythmia may give way to ventricular fibrillation [5]. 
Other adverse effects of digitalis include gastrointestinal effects such as anorexia, 
nausea, and vomiting. CNS disturbances such as headache, fatigue, and confusion may 
also occur. Visual disturbances include obscure vision, modification of color perception, 
and haloes of dark objects [13]. 
4. Overview of Clinical Trials 
Although the inotropic properties of digitalis were described as far back as 1785, its 
place in AMI management is still controversial. Reexamination of certain previous 
observational studies on digitalis reveal an association between its use and an increase in 
mortality. Other studies, however, show no effect on mortality. Recently it has been 
revealed that digitalis improves symptoms and positively affects the neurohormonal system 
in patients with LV systolic dysfunction [1]. The Digitalis Investigator Group (DIG) [56] 
compared digitalis to placebo with regard to all-cause mortality among 7788 CHF patients 
without rhythm disturbances. CHF was caused by ischemic disease in 70% of the study 
patients, and greater than 90% of the patients were also treated with ACE inhibitors and/or 
diuretics. Overall, the study revealed that digoxin did not reduce total mortality. Digoxin- 
treated patients, however, did have less deaths due to CHF and less combined 
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hospitalizations and deaths due to heart failure. There was a suggestion, however, of 
increased deaths from supposed arrhythmia or MI in the digoxin group. 
The current recommendation for Digoxin use, based on clinical experience, advises 
the administration of digoxin to certain post-MI patients who have supraventricular 
arrhythmias or CHF that is not responsive to ACE inhibitors or diuretics [1]. 
9. Diuretics 
The patient hospitalized for AMI should be treated with diuretics if he/she suffers 
from heart failure. Usually, intravenous furosemide is administered. The patient with 
heart failure should be administered an afterload reducing agent as well [1]. 
10. Hypolipidemic Agents 
Recent trials have shown that substantially lowering cholesterol levels in patients at 
high risk for coronary heart disease or patients with established, but stable coronary heart 
disease, with the use of 3-hydroxy-3-methylglutaryl-coenzyme A reduces cardiovascular 
morbidity and mortality [57-59]. Hence, it is well established that the long term 
management of the patient status post-AMI should involve lipid reduction. ACC/AHA 
guidelines for long term management of the patient after AMI state that in addition to 
receiving aspirin, a beta-blocker, and a selected dose of an ACE inhibitor after AMI, the 
patient should be instructed about weight control and educated about a diet low in saturated 
fat and cholesterol. If, despite dieting, the patient maintains a low-density lipoprotein 
(LDL) cholesterol measurement greater than 130 mg/dL, drug therapy with the goal of 
reducing LDL to less than 100 mg/dL should be initiated. Additionally, smoking cessation 
is essential, and an ultimate goal of exercising for 20 minutes, three times a week, at the 
level of brisk walking, should also be met [1]. 
However, it is still uncertain whether lipid-lowering drugs should be administered 
immediately after AMI, in doses that would acutely lower lipid levels. Such reduction 
might stabilize coronary plaques and lessen early, recurrent ischemic events. The MIRACL 
study, currently underway, has been designed to address this issue [60]. 
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II. Statement of Purpose and Hypothesis 
We hypothesized that the availability of resources influences the type of care 
administered to patients with AMI. Hence, we evaluated and compared the procedural and 
pharmacologic management of patients in hospitals of different sophistication levels. 
Additionally, we hypothesized that application of clinical guidelines in practice is imperfect 
and that pharmacologic treatment does not always conform to the recommendations of these 
published guidelines. Thus, we assessed for trends in pharmacologic treatment over time 




A. Experimental Design 
To evaluate our hypothesis, we analyzed data from the CHAMP study, a 
prospective post-MI study in the VA sector which evaluated warfarin and aspirin in 
combination against aspirin. We determined utilization rates of (1) cardiac procedures 
including PTCA and CABG and (2) pharmacotherapies including ACE inhibitors, 
antiarrhythmics, beta-blockers, calcium channel blockers, digitalis, diuretics, nitrates, 
and hypolipidemic agents in patients with proven myocardial infarction (transmural or non¬ 
transmural) who participated in the CHAMP study. Utilization rates are computed per 
calendar year, according to level of hospital sophistication, and analyzed over the course of 
the study (1993-1997). Ensuing trends are plotted. A determination is made as to whether 
the resources available at the respective hospitals influenced patient care, whether these 
practice patterns changed over time, and whether trends in clinical practice reflect the results 
of concurrent clinical trials. 
B. Data Source: The CHAMP Study 
The CHAMP study, designed by Michael Ezekowitz, M.D., Ph.D. and Louis 
Fiore, M.D. provides a unique opportunity to test our hypotheses. Designed to 
demonstrate whether the combination of oral anticoagulation and antiplatelet therapy (i.e., 
warfarin and aspirin) is superior to aspirin alone in reducing overall mortality following 
acute myocardial infarction, this study was a two-arm, prospective, randomized, unblinded 
trial. Approximately 5000 patients admitted to the participating VA hospitals between 
1992 to 1998 with proven myocardial infarction8 were randomized to receive either 
warfarin and aspirin in combination or aspirin alone. 
8 For the CHAMP study, the diagnosis of AMI is defined as the presence of two of the following : chest 
pain discomfort typical of AMI, EKG changes typical of AMI and blood enzyme changes typical of AMI (at 
least one of the following: MB isoenzyme of creatine kinase in excess of 4 % of the total creatine kinase 
level, elevated total lactic dehydrogenase with an abnormal reversal of the ratios of LDH 1 to LDH 2 or the 
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All hospitalized patients with a diagnosis of AMI within the previous 14 days were 
screened for admission to the study. Patients were considered ineligible for enrollment 
based on specific exclusion criteria that are listed in Table A. 
None of the following conditions were reasons for exclusion: history of coronary 
artery bypass surgery, coronary artery angioplasty either before or after the index AMI and 
use of thrombolytic therapy for any AMI. Additionally, there was no age cutoff in this 
study. 
All eligible patients were asked to participate in the study and if the patient and his 
physician agreed to randomization, an “Informed Consent Form” and “Baseline Data 
Form” were completed. Hence, baseline data were obtained on all eligible consenting 
patients within 14 days of the index AMI and prior to hospital discharge. The information 
included most of the known predictors for long-term survival following AMI. The baseline 
form recorded information about subjects’ demographics, smoking, and medical history. 
Additional information included the extent, location and complications (if any) of the index 
infarction; ejection fraction; serum chemistries; medical therapy; and invasive procedures. 
Not included were predictors that were not routinely available on all patients such as a post 
AMI exercise tolerance test or results of cardiac catheterization. 
Once consent and baseline data were obtained, the local study coordinator would 
contact the coordination center and the patient would be randomized. At this time the 
patient’s “Randomization Form” would be completed. 
The assigned therapy was initiated immediately. All patients were contacted every 
three months and seen every six months to complete the “Follow-up Visit Form.” The 
follow-up form recorded information about study withdrawal and compliance to assigned 
therapy. Additionally, it included information on any intercurrent events as well as 
procedures/conditions since the last visit. 
elevation of two or more of lactic dehydrogenase, creatine kinase or aspartate transaminase to twice the 
upper limit of normal without an obvious other cause for the rise). 
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C. Data Acquisition Specifically Related to This Project 
Baseline data (collected within two weeks from index AMI) as well as three-month 
follow-up data were available for our investigation for the six years of the CHAMP study 
(1993-1998). Information collected at these times concerning the cardiac procedures and 
pharmacologic treatment for the index AMI served as the basis for our analysis. Table B 
lists the categories of the information which were collected from the CHAMP database and 
analyzed based on the year that the patient was enrolled into the study and based on what 
hospital type the patient was initially treated at. 
Seventy-five VA hospitals throughout the U.S., including both large university- 
associated VA medical centers as well as smaller hospitals, participated in the study. 
Hence, participating hospitals differed in their available resources and capabilities. In 
preparation for our analysis, these hospitals were contacted by telephone to determine their 
capabilities for cardiac care. Hospitals were grouped into three classes according to level of 
resources available: Group 1 hospitals did not have a cardiac catheterization laboratory and 
did not perform cardiovascular surgery; Group 2 hospitals performed cardiac 
catheterization procedures, but did not perform cardiac surgery or angioplasty on site; 
Group 3 hospitals provided both cardiac catheterization procedures and cardiac surgery on 
site. This Categorization of participating hospitals fashion enabled us to analyze data by 
level of hospital sophistication. This classification system is depicted in Table C. 
D. Statistical Methods 
Trends in procedure use were examined at the time of randomization and at three 
months post randomization, by year of enrollment (1992-1997), and by hospital 
sophistication. Medication use was analyzed by year of enrollment and by hospital 
sophistication. Chi-square analyses were used to test for crude differences in procedure 
and pharmacologic utilization across hospital categories and across years of enrollment. A 
Mantel-Haenszel Extension Test for linear trend was used to examine trends in procedure 
utilization and medication use across years of study enrollment. For the analysis of 
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medication/procedure use by hospital type, percentages of the total population randomized 
to each hospital type are reported for each medication or procedure use. For the analysis of 
management by year of enrollment, percentages of the total enrolled trial population were 




A. Champ Enrollment by Hospital Cardiac Capability (Fig 1) 
Participating hospitals were divided into three groups. Group 1, which contained 
22.4% of patients recruited in the CHAMP study, had no cardiac catheterization laboratory. 
Group 2, which comprised 22.6% of patients recruited, had a cardiac catheterization 
laboratory but did not have the capability to perform cardiac surgery. Group 3, the most 
advanced hospital grouping, encompassed 54.9% of the recruited patients and had the 
capability for diagnostic catheterization as well as both catheter based and surgical 
revascularization. 
B. Champ Enrollment 1993-1998 (Fig 2) 
The percent of patients enrolled in the CHAMP study was computed for each study 
year. In 1993, 700 patients (14.8% of the patients) were randomized into the study. 
Enrollment increased in 1994 to 1115 patients (23.5% of the total) and further increased to 
1125 patients in 1995 (23.9%). For the last three years of the study, however, enrollment 
dropped to 847 patients in 1996 (17.9%), 817 patients in 1997 (17.3%) and to the lowest 
enrollment of 129 patients (2.7% of total) in 1998. For the analysis of procedure and 
medication use over time, we excluded data from 1998 because of the small number of 
patients recruited in this year. Patient data from 1998, however, are included in the 
analysis of management by hospital type, as in this analysis all patients recruited over the 
1993-1998 time period are considered together. 
C. CHAMP Trends in Procedure Use 
1. CHAMP CABG Rates 
a. Total CABG (Within 90 days) Post-MI by Year (Fig 3) 
The trend in CABG use over time increased in a statistically significant manner over 
time: 16.6%, 19.0%, and 21.4% in 1993, 1995, and 1997, respectively (p(trend) =0.001). 
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b. CABG Rates by Hospital Type 
1. Early (Within 14 Days) vs. Later (Between 14-90 Days) 
CABG Post-MI bv Hospital Type (Fig 4) 
CABG procedure rates were stratified according to the categories of “early CABG” 
— CABG within 14 days of index infarct—and “later CABG”—CABG between 15-90 days 
following index infarct. There is a significant difference in the percent of patients 
undergoing both early and later CABG when rates are analyzed by hospital type. 
Unsophisticated hospitals (group 1) have the lowest rate of early CABG but highest rate of 
later CABG. Sophisticated hospitals (group 3), however, have the highest rate of early 
CABG and a lower rate of later CABG. Yet, when all CABG procedures performed within 
90 days of index MI are considered together, unsophisticated and sophisticated hospitals 
have comparable rates. 
Only 1.8% of the patients treated in Group 1 hospitals underwent early CABG. 
The percent is higher (3.3%) for patients admitted to Group 2 hospitals, and highest 
(7.7%) among patients treated at Group 3 hospitals (p=0.001). However, the results are 
very different for later CABG (CABG between 14-90 days). Later CABG rates were 
highest in patients initially admitted to group 1 hospitals (19.2%). Rates of later CABG 
were significantly lower in Group 2 (13.0%) and group 3 (14.6%) (p=0.001). 
2. Total CABG (Within 90 Days) Post-MI bv Hospital Type (Fig 4) 
When both early and later CABG rates are considered together, group 1 (19.3%) 
and group 3 hospitals(20.9%) have comparable rates, whereas group 2 hospitals (15.0%) 
have a rate that is significantly lower (p=0.001). 
c. CABG Rates by Hospital Type bv Year 
1. Early CABG (Within 14 Days Post-MI) bv Hospital Type by 
Year (Fig 5) 
In group 3 hospitals, the rates of cardiac surgery increased significantly over time, 
ranging from 4.1% in 1993 to 6.4% in 1995 to 11.4% in 1997 (p(trend)=0.001). Group 1 
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and group 2 hospitals varied by year. In 1993 early CABG rates were 2.6% and 3.7% for 
hospital groups 1 and 2, respectively. In 1995, the group 1 rate decreased (0.8%), and the 
rate in group 2 increased (4.6%). In 1997, CABG rates increased in group 1 hospitals 
(1.9%) but decreased in group 2 (1.0%). 
2. Later CABG (Between 14-90 Days) Post-MI by Hospital Type 
by Year (Fig 6) 
In contrast to the rates of early CABG that increased over time in sophisticated 
hospitals, the rates of later CABG increased dramatically over time in unsophisticated 
hospitals. Later CABG rates in group 1 hospitals ranged from 12.9% to 19.3% to 27.5% 
in 1993, 1995, and 1997, respectively (p(trend)=0.001). In the other hospital groups rates 
were relatively unchanged (11.2% to 12.6% to 13.5% in 1993, 1995, and 1997, 
respectively for group 2 hospitals, (p(trend)=0.517) and 16.1% to 15.1% to 13.5% in 
1993, 1995, and 1997, respectively for group 3 hospitals (p(trend)=0.571). 
3. Total CABG (Within 90 Days) Post-MI by Hospital Type by 
Year (Fig 7) 
Overall, there was a significant increase in total CABG over time in group 1 
hospitals, whereas total CABG in group 2 and group 3 hospitals remained remarkably 
constant over time. Group 1 hospitals increased their rates of total CABG over time by 
102%, from 14.0% to 18.8% to 28.3% in 1993, 1995 and 1997, respectively (p 
(trend)=0.001). In group 2 hospitals, no significant trend is seen for total CABG rate; total 
CABG rates over time ranged from 13.9% to 15.6% to 13.7% in 1993, 1995, and 1997, 
respectively (p(trend)=0.686). In group 3 hospitals, total CABG rates over time increased 




2. CHAMP PTCA Rates 
a. Total PTCA (Within 90 days) Post-MI by Year (Fig 8) 
Overall, PTCA use increased significantly from 1993 to 1997, with 15.4% of patients 
undergoing PTCA in 1993, 21.6% in 1995 and 29.3% in 1997 (p(trend)=0.036). 
b. PTCA Rates by Hospital Type 
1. Early (Within 14 days) vs. Later (Between 14-90 Days) 
PTCA Post-MI by Hospital Type (Fig 9) 
PTCA procedure rates, like those of CABG, were stratified into two classes: early 
PTCA — PTCA within 14 days of index infarct —and later PTCA—PTCA between 15-90 
days following index infarct. 
Early PTCA rates increased significantly with increasing hospital sophistication 
level, as demonstrated by rates of 5.0%, 8.6%, and 23.5% for groups 1, 2, and 3, 
respectively (p=0.001). Later PTCA remained constant among the three hospital types, 
however, with rates of 9.6%, 9.3%, and 8.8% for groups 1, 2, and 3, respectively 
(p=0.75). 
2. Total PTCA (Within 90 days) Post-MI bv Hospital Type 
(Fig. 9) 
Overall, however, when both early and later PTCA utilization rates are considered 
together, there is a significant increase with increasing hospital sophistication. Group 3 
hospitals had the greatest utilization rates (29.5%), group 2 in the middle (16.5%) and 
group 1 the least (13.4%) (p=0.001). 
c. PTCA Rates by Hospital Type by Year 
1. Early PTCA (Within 14 Days) Post-MI by Hospital Type 
by Year (Fig 10) 
Early PTCA rates increased significantly over time in group 3 hospitals, ranging 
from 15.9% to 22.5% to 29.8% in 1993, 1995, and 1997, respectively (p (trend)=0.001). 
In group 2 hospitals a significant upward trend is seen in early PTCA rates as well, with 
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rates ranging from 3.7% to 6.7% to 12.3% in 1993, 1995, and 1997, respectively 
(p(trend)=0.006). In group 1 hospital types, however, rates of early PTCA did not 
change significantly over time, with rates ranging from 5.2% to 2.9% to 3.8% in 1993, 
1995 and 1997, respectively (p(trend)=0.366). 
2. Later PTCA (Between 14-90 Days) Post-MI by Hospital 
Type bv Year (Fig 11) 
Rates of later PTCA increased significantly over time in group 1 hospitals, ranging 
from 3.4% to 6.3% to 15.0% in 1993, 1995, and 1997, respectively (p(trend)=0.004). 
There was no significant linear trend, however, in group 2 or group 3 hospitals. Group 2 
hospitals had utilization rates of 7.2%, 6.9%, 10.8%, 9.8% and 11.3% in years 1993- 
1997, respectively (p(trend)=0.102). Group 3 hospitals had utilization rates of 8.2%, 
9.6%, and 7.7% in 1993, 1995, 1997, respectively (p(trend)=0.924). 
3. Total PTCA (Within 90 Days) Post-MI bv Hospital Type 
bv Year tFig 121 
All three hospital types show significant increases in total PTCA rates over time. 
Total PTCA rates in group 1 hospitals were 8.3%, 15.9%, 8.3%, 15.0%, and 18.2% from 
1993-1997, respectively (p(trend)=0.036). Total PTCA rates in group 2 hospitals are 
9.7%, 14.9%, 16.0%, 17.2%, 22.8% from 1993-1997, respectively (p(trend)=0.Q01). 
Total PTCA rates in group 3 hospitals were 22.1%, 26.5%, 28.7%, 31.6%, and 36.2% 
from 1993-1997, respectively (p(trend)=Q.Q01). 
D. CHAMP Trends in Medication Use 
1. Thrombolytics 
a. Thrombolytic Use bv Year (Fig 13) 
Thrombolytic use was relatively stable from 1995 to 1997. Use increased from 
1993 (29.6%) to 1994 (36.0%) and then decreased again in 1995 (28.7%). Usage 
increased slightly in 1996 (29.7%) and decreased in 1997 (29.6%), (p (trend = 0.071). 
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b. Thrombolytic Use by Hospital Type (Fig 14) 
There is a significant decrease in thrombolytic use with increasing hospital 
sophistication level. Group 1 hospitals had the greatest thrombolytic usage (33.5%), group 
2 hospitals had a lower usage (32.4%) and group 3 had the lowest thrombolytic usage 
(29.3%) (p=0.026). 
c. Thrombolytic Use by Hospital Type by Year (Fig 15) 
Overall, thrombolytic utilization trended downward in group 1 hospitals 
(p(trend)=0.006), but trended upward among group 2 hospitals (p(trend)=0.001). For 
group 3 hospitals, utilization also trended downward (p(trend) = 0.005). 
2. ACE Inhibitors 
a. ACE Inhibitor Use by Year (Fig 16) 
Our data show a significant increase in ACE inhibitor use from 1993 to 1997. In 
1993, 26.4% of study patients were treated with ACE inhibitors, and increased to 31.0% in 
1995, and 43.4% in 1997 (p (trend)= 0.001). 
b. ACE Inhibitor Use by Hospital Type (Fig 17) 
There was no significant difference in ACE Inhibitor use by hospital type. Group 3 
hospitals had the highest use of ACE inhibitors (33.3%), with group 1 (32.8%) and Group 
2 (31.3%) hospitals having the lowest utilization rates (p=0.503). 
c. ACE Inhibitor Use By Hospital Type By Year (Fig 18) 
Analysis of ACE inhibitor use according to hospital type and year reveals that there 
was a significant increase in ACE inhibitor use across years for all hospital types. Group 1 
utilization rates increased over time: 27.5%, 30.8%, and 44.0% for 1993, 1995, and 
1997, respectively (p(trend)=0.029). Group 2 utilization rates increased over time: 
25.5%, 28.2%, and 46.7% for 1993, 1995, and 1997, respectively (p(trend)=0.001). 
Group 3 utilization rates increased as well: 26.2%, 31.8%, and 41.6% for 1993, 1995, and 




a. Beta-Blocker Use by Year (Fig. 19) 
Beta-Blocker use significantly increased from 1993 to 1997. In 1993, 63.4% of 
patients were treated with beta-blockers. This number increased to 71.1% in 1995 and to 
79.2% in 1997 (p(trend)= 0.001). 
b. Beta-Blocker Use by Hospital Type (Fig 20) 
There is a significant difference in beta-blocker use according to hospital type. Use 
is highest in group 2 hospitals (74.7%) and lowest in group 1 hospitals (63.6%), with an 
in-between rate ( 73.2%) in group 3 hospitals ( p=0.001). 
c. Beta-Blocker Use by Hospital Type by Year (Fig 21) 
Analysis of beta-blocker use according to hospital type and year reveals that there 
was a significant increase in beta-blocker use over time for all hospital types. Group 1 
utilization rates increased from: 51.3% to 63.6% to 74.8% for 1993, 1995, and 1997, 
respectively (p(trend)=0.001). Group 2 utilization rates increased as well: 70.3%, 74.0%, 
and 83.4% for 1993, 1995, and 1997, respectively (p(trend)=0.001). So too, group 3 
utilization rates increased over time: 67.1%, 72.5%, and 78.8% for 1993, 1995, and 1997, 
respectively (p(trend)=0.001). 
4. Calcium Channel Blockers 
a. Calcium Channel Blocker Use by year (Fig 22) 
Data show a significant decrease in calcium channel blocker use between 1993- 
1997. Use is highest in 1993 (32.3%), but decreased in 1995 (25.4%), and in 1997 
(17.8%) (p(trend)= 0.001). 
b. Calcium Channel Blocker Use by Hospital Type (Fig 23) 
No differences were found for calcium channel blocker use by hospital type:, 25%, 
22.9%, and 26.1% for groups 1,2, and 3, respectively (p=0.127). 
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c. Calcium Channel Blocker Use bv Hospital Type by Year (Fig 24) 
Analysis of calcium channel blocker use according to hospital type and year reveals 
that there was a significant decrease in calcium channel blocker use across years for all 
hospital types. Group 1 utilization rates decreased over time: 34.7%, 23.4%, and 19.5% 
for 1993, 1995, and 1997, respectively (p(trend)=0.001). Group 2 utilization rates 
decreased overtime as well: 27.9%, 22.7%, and 17.1% for 1993, 1995, and 1997, 
respectively (p(trend)=0.001). Group 3 utilization rates also decreased over time: 33.2%, 
27.3%, and 17.5% for 1993, 1995, and 1997, respectively (p(trend)=0.001). 
5. Digitalis 
a. Digitalis Use by Year (Fig 25) 
Data are suggestive for a decreasing trend in digitalis use from 1993 to 1998. In 
1993, digitalis use was at its highest, 8.7%, decreasing to 7.5% in 1995 and 6.7% in 
1997, (p(trend)= 0.124). 
b. Digitalis Use by Hospital Type (Fig 26) 
Data show a significant difference in digitalis use according to hospital type. 
Digitalis was greatest in group 3 (8.4%), compared with group 2 (8.0%) and group 1 
(5.1%) hospitals (p= 0.001). 
c. Digitalis Use by Hospital Type bv Year (Fig 27) 
Analysis of digitalis use according to hospital type and year reveals that there was a 
significant decrease in digitalis use across years in group 3 hospitals only. Group 1 
utilization rates decreased over time: 5.7%, 5.4%, and 4.4% for 1993, 1995, and 1997, 
respectively (p(trend)=0.077). Group 2 utilization rates wavered over time: 6.1%, 10.1%, 
and 6.6% for 1993, 1995, and 1997, respectively (p(trend)=0.851). Group 3 utilization 





a. Diuretic Use by Year (Fig 28) 
We found no apparent linear trend in diuretic use over time. Rather, diuretic use 
shows a wavering pattern over time, with the initial rate in 1993 (17.3%) being lower than 
the final rate in 1997 (19.4%). The rate decreases from 1993 to 1994 (16.0%), increases 
by 1995 (17.1%), and then drops in 1996 (13.9%), only to reach its highest level in 1997, 
(p(trend)= 0.579). 
b. Diuretic Use by Hospital Type (Fig 29) 
Data show a significant difference in diuretic use according to hospital 
sophistication. Use was greatest in group 1 (19.9%) lower in group 2 (15.7%) and 
slightly lower in group 3 (15.6%), ( p= 0.004). 
c. Diuretic Use by Hospital Type by Year (Fig 30) 
Analysis of diuretic use reveals that there was no uniform trend in the use of these 
agents by years or by hospital type. Group 1 utilization rates fluctuated over time: 11.9%, 
24.6%, and 22.6% for 1993, 1995, and 1997, respectively (p(trend)=0.212). Group 2 
utilization rates fluctuated over time as well: 23.0%, 16.0%, and 18.0% for 1993, 1995, 
and 1997, respectively (p(trend)=0.895); while, group 3 utilization rates remained 
relatively stable over time: 17.4%, 14.0%, and 18.8% for 1993, 1995, and 1997, 
respectively (p(trend)=0.966). 
7. Nitrates 
a. Nitrate Use by Year (Fig 31) 
Data show a significant decreasing trend in nitrate use over time. Although initially, 
utilization minimally increases from 1993 (78.5%) to 1994 (78.7%), from 1994 until 1997 
there is a significant decline in nitrate use. Use declined to 77.8% in 1995, and 71.6% in 
1997, (p(trend)= 0.001). 
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b. Nitrate Use by Hospital Type (Fig 32) 
Data show a significant difference in nitrate use between hospital type 1 (80.3%) 
and the other hospital types, hospital type 2 (75.1%) and hospital type 3 (75.1%) 
(p=0.002). 
c. Nitrate Use by Hospital Type by Year (Fig 33) 
Analysis of nitrate use according to hospital type and year reveals that there was a 
significant decrease in nitrate use across years for groups 1 and 3, but not for group 2. 
Group 1 utilization rates decreased overtime: 78.2%, 87.1%, and 69.2% for 1993, 1995, 
and 1997, respectively (p(trend)=0.005). Group 2 utilization rates remained relatively 
stable: 78.2%, 75.6%, and 71.1% for 1993, 1995, and 1997, respectively 
(p(trend)=0.109); while group 3 utilization rates decreased over time: 78.8%, 74.9%, and 
72.7% for 1993, 1995, and 1997, respectively (p(trend)=0.001). 
8. Hypolipidemic Agents 
a. Hypolipidemic Agent Use by Year (Fig 34) 
Data show a significant increase in the use of lipid lowering medication between 
1993-1997. In 1993, utilization rate was 8.7%, increasing to 14.2% in 1995, and 39.2% 
in 1997, (p(trend)= 0.001). 
b. Hypolipidemic Agent Use by Hospital Type (Fig 35) 
Data show a significant difference in lipid lowering medication utilization according 
to hospital type. Use was highest in group 2 (21.3%), slightly lower in group 3 (20.9%) 
and lowest in group 1 (15.5%), (p= 0.001). 
c. Hypolipidemic Agent Use by Hospital Type bv Year (Fig 36) 
Analysis of hypolipidemic agent use according to hospital type and year reveals that 
there was a significant increase in hypolipidemic agent use across years for all hospital 
types. Group 1 utilization rates increased over time: 5.7%, 12.5%, and 35.2% for 1993, 
1995, and 1997, respectively (p(trend)=0.001). So too, group 2 utilization rates increased 
overtime: 9.1%, 15.6%, and 40.0% for 1993, 1995, and 1997, respectively 
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(p(trend)=0.001), and group 3 utilization rates increased as well: 10.3%, 14.4%, and 




A. Cardiac Procedures 
Our results showed that over a six year period (1993-1997), cardiac procedures 
were increasingly employed in the management of VA patients diagnosed with AMI. 
PTCA and CABG, when considered together, increased by 59% in the time period under 
investigation (32% in 1993, 51% in 1997). Considered individually, both CABG and 
PTCA utilization increased over the six year study period; CABG increased by 29% 
(16.57% in 1993, 21.42% in 1997) (Figure 3), and PTCA increased by 90% (15.43% in 
1993, 29.25% in 1997) (Figure 8). This pattern of increased procedure application in the 
treatment of patients with ischemic heart disease is evident in all hospitals groups in our 
study (Figure 7, Figure 12) and is consistent with the trend that has been observed in the 
United States over the last two decades. Statistics collected between 1980 and 1992 
revealed a 163% increase in coronary angiography rates and a 102% increase in CABG 
rates [61]. 
The question arises as to whether this aggressive approach with regard to cardiac 
procedures translates into better outcomes for AMI patients. Tu and colleagues [62] 
address this issue with a comparison of the one-year mortality rate in a cohort of 
aggressively managed patients from the United States to a less aggressively managed 
cohort from Ontario, Canada. They found that despite the differences in management, the 
two cohorts had virtually identical one-year mortality rates. They concluded that, overall, 
their study favored the more conservative approach to revascularization that is employed in 
Canada. 
However, as pointed out by Krumholz, in determining the overall impact of 
coronary revascularization, one must consider not only mortality rates, but also the 
patients’ quality of life and functional status, as well as the costs incurred [63]. Hence, 
analyzing the outcome data for the patient population included in our study would provide 
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important information for interpreting the potential benefits of our increasingly aggressive 
management appraoch. This analysis is currently underway but is beyond the scope of this 
work. 
Although hospitals of all sophistication levels have increased their utilization of 
cardiac procedures overall, our study reveals a significant difference in procedure utilization 
based on hospital sophistication level. Patients admitted to hospitals of highest 
sophistication (group 3) with capabilities for both cardiac catheterization and surgery, who 
were treated with a procedure, were most likely to be treated with “early” PTCA (within 14 
days following index MI) rather than “later” PTCA (between 14-90 days following index 
MI), “early” CABG (within 14 days following index MI), or “later” CABG (between 14 - 
90 days following index MI). In 1997, 29.82% of patients randomized to group 3 
hospitals were treated with early PTCA whereas 7.73% had later PTCA, 11.41% had early 
CABG and 13.53% had later CABG. Totaling all early PTCAs performed in the six years 
under investigation, the rate of early PTCA increased significantly with increasing level of 
hospital sophistication: 5.04% in group 1, 8.55% in group 2, and 23.45% in group 3 
(p=0.001) (Figure 9). 
Patients admitted to less sophisticated hospitals (groups 1 and 2), however, and 
treated with a procedure, were most likely to be referred out to more sophisticated hospitals 
and treated with “later” CABG. In 1997, 27.25% of patients admitted to group 1 hospitals 
were treated with later CABG, whereas 1.9% had early CABG, 15.03% had later PTCA 
and 3.77% had early PTCA. Similarly, in 1997, 13.45% of patients admitted to group 2 
hospitals were treated with later CABG, whereas 0.95% had earlier CABG, 11.33% had 
later PTCA and 12.32% had early PTCA. Totaling all later CABG procedures performed 
in the six years under investigation, the rate of later CABG is highest in group 1 hospitals- 
19.16% in group 1, 13% in group 2, and 14.64% in group 3 (p=0.001) (Figure 4). 
Overall, our results show that patients admitted to the most sophisticated hospitals 
and treated with a procedure tend to be treated “early,” whereas those admitted to 
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unsophisticated and intermediate hospitals are treated “later.” Hospitals of greatest 
sophistication favor PTCA, whereas less sophisticated hospitals favor CABG. (The latter 
trend is consistent with recommendations that PTCA should be performed within 60-90 
minutes following diagnoses of AMI, and hence, later PTCA would not be advisable). 
This evidence of a discrepancy in procedural care based on the resources available 
supports the findings of Wright et al. who reported that rates of cardiac catheterization (OR 
3.07; 95% Cl 2.87-3.28), CABG (OR 1.48; 95% Cl 1.33-1.65), and PTCA (OR 2.93; 
95% Cl 2.57-3.34) were significantly higher in patients admitted to sophisticated versus 
relatively unsophisticated hospitals [64]. Our study shows, however, that although both 
CABG and angioplasty rates are higher in patients admitted to sophisticated hospitals, 
when all data are pooled over the six year time period, procedure use increases in 
unsophisticated hospitals. In 1996 and 1997, unsophisticated hospitals had higher CABG 
rates than sophisticated hospitals (1996, group 1=25%, group 3=22.72%; 1997, group 
1=28.30%, group 3=22.6%) (Figure 7). PTCA rates, however, were higher in more 
sophisticated hospitals (1996, group 1 = 15%, group 2 = 31.64%; 1997, group 1 = 18.24%, 
group 3 = 36.24%) (Figure 12). 
Wright et al. also studied patient outcomes in VA facilities by hospital sophistication 
level. They concluded that patients admitted to relatively unsophisticated hospitals had 
significantly higher mortality compared with patients initially admitted to more 
sophisticated hospitals [64]. Other studies, however, have found no differences in 
mortality based on the level of hospital sophistication [65-67]. The question of whether 
variation in hospital sophistication level affects patient outcome is most significant for the 
VA health care system, as our study showed that a substantial minimum of VA patients (in 
the CHAMP study 22%) with AMI are being admitted to relatively unsophisticated 
hospitals, while Wright et al showed that 35.5% of patients with AMI were admitted to 
relatively unsophisticated hospitals [64]. 
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The relationship between accessibility to services and patient outcome may be 
important in the private sector as well. In this era of emphasis on reducing costs, 
increasing efficiency, and preserving quality of care, health care is becoming more 
regionalized as health-care facilities have begun to consolidate. “Centers of excellence” - 
i.e., discrete centers which harbor specialized medical technologies necessary for various 
medical interventions, to which other facilities must refer —have become the regional 
mainstay for delivering advanced care. Concern arises that this trend may limit equal 
access of technology to all patients and may affect patient outcome [64]. Hence, the 
relationship between resources and patient outcome is one which has not been fully 
established and requires further investigation. 
B. Thrombolytics 
Thrombolytic usage increased with decreasing level of sophistication (p=0.026). 
This result is concordant with low rates of PTCA in the hospitals with high rates of 
thrombolysis. Thrombolytic use remained relatively uniform from 1993-1997. 
p(trend)=0.071. Over time, group 1 (p(trend)=0.006) and group 3 hospitals 
(p(trend)=0.005) showed a significant decrease in the use of thrombolytics, whereas 
increased use was found in group 2 hospitals (p(trend)= 0.001). 
C. Pharmacology 
The results of Wright et al. suggest that “on-site cardiac technology may be a 
measure of a hospital’s ‘total treatment effect’ received by patients initially admitted to these 
facilities for which revascularization procedures are but one indicator.” [64] If this were 
true, differences should be observed not only in procedural care of patients but also in 
pharmacologic treatment of patients, depending on hospital sophistication. In our analysis, 
however, significant trends in medication use were uniform among hospital types (figures 
18, 21, 24, 36). 
Medication utilization trends from 1993-1997 show a significant increase in the use 
of ACE inhibitors (figure 16), beta-blockers (figure 19),and lipid lowering agents (figure 
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34), as well as a significant decrease in the use of calcium channel blockers (figure 22). 
These trends conform to the guidelines developed from published clinical trials that were 
carried out during the time period under investigation. As mentioned above, these trends 
were seen in all hospital groups indicating that, with regard to pharmacologic treatment, 
clinical trial results are being translated into patient care in all VA hospitals, independent of 
“on-site cardiac technology.” 
ACE inhibitor use significantly increased by 64% from 1993 (26.43%) to 1997 
(43.38%) (p=0.001), reflecting evidence from clinical trials that ACE inhibitors increase 
both short-term and long-term survival in AMI patients [23,24,42-44]. This trend was 
observed in all hospital groups (figure 18). 
Similarly, the use of beta-blockers increased by 25% from 1993 (63.43%) to 1997 
(79.19%) (p=0.001). This increasing trend was also seen in all hospital groups (figure 21) 
reflects the results of clinical trials that show that beta-blockers reduce morbidity and 
mortality following AMI [39-41]. 
Most impressive, utilization of hypolipidemic agents increased by 350% from 1993 
(8.71%) to 1997 (39.22%) (p=0.001). This increase reflects the results of recent trials that 
show that substantially lowering cholesterol levels in patients at high risk for coronary heart 
disease and in patients with established but stable heart disease, reduces cardiovascular 
morbidity and mortality [57-59]. This increasing trend was also found in all hospital groups 
(figure 36). 
Calcium channel blocker use decreased by 45% from 1993 (32.29%) to 1997 
(17.75%), as no studies support the use of these agents in early treatment of AMI or in 
secondary prevention for most AMI patients. In fact, in some patients this class of drugs 
may be harmful and can exacerbate ischemia and cause death from myocardial depression 





Our data suggest a downward trend in digitalis use from 1993 (8.71%) to 1997 
(6.73%) (p=0.124), reflecting recent evidence that digitalis may not reduce total mortality 
following AMI [56] and is recommended only in patients who have supraventricular 
arrhythmias or CHF that is not responsive to ACE inhibitors or diuretics [1]. This trend 
was significant, however, only in group 3 hospitals (p=0.007) (figure 27). 
Despite the uniform trends seen in all hospital groups with regard to medication 
usage over time, significant differences were observed in the rates of beta-blocker and 
hypolipidemic agent utilization among hospital groups (figures 20 and 35). Although 
utilization over time did increase for both beta-blockers and hypolipidemic agents in all 
hospital groups, group 1 hospitals had significantly lower usage of both these agents when 
compared with the more sophisticated hospital groups (p=0.001 for both medications). 
Hence, unsophisticated hospitals may need to further increase their use of beta-blockers 
and hypolipidemic agents. 
D. Study Strengths 
One of the main strengths of our study was the six year time span over which data 
were collected. Employing data from the VA health care system represents an additional 
strength when analyzing rates of procedure use, as issues of patient insurance affecting 
procedure availability or provider-driven induced demand are not of concern. In the VA 
system all veterans eligible for VA care can obtain procedures independent of financial 
status. Additionally, since VA physicians are salaried, physician driven-induced demand 
does not contribute to rates of procedure use across hospital types. [64]. 
E. Study Limitations 
It is important to note that this is an observational study with certain limitations that 
will need to be resolved with subsequent analyses and further investigation before the 
clinical implications can be firmly established. Although did not adjust for varied patient 
characteristics and severity of patient illness across hospital groups, crude analyses reflect 
that patient characteristics (i.e., systolic hypertension, diastolic hypertension, Q-wave MI, 
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significant CHF, ischemia post-MI, arrhythmia, Caucasian race, prior MI, history of 
smoking, diabetes, age >60 ) did not differ significantly by hospital sophistication level 
(data not shown). 
In addition, we did not control for the fact that the severity of patient illness may 
have differed according to year of hospital study. Other clinical trials being conducted at 
the same time as the CHAMP study may have led to a competition for patients, and 
depending on which trial was being conducted each year, CHAMP may have randomized 
sicker patients some years than others. 
F. Conclusion 
Overall, analysis of CABG and PTCA utilization rates reveals differences over time 
and according to hospital sophistication. These results highlight the need for outcome 
analyses, as the impact of these findings will be better understood when outcome 
analyses are performed. Results of these analyses may have far-reaching effects on efforts 
to regionalize heath care in both the VA health care system and the private sector. With 
regard to pharmacologic interventions, it appears that trends in treatment are rather uniform 
across different hospital types and follow the results of clinical trials. Since clinical trial 
results are ultimately translated into guidelines, our data suggest that, over time, the trends 
in the pharmacologic care delivered by our country’s largest HMO, the VA system, to 
patients diagnosed with AMI, adhere to the AHA/ACC clinical guidelines that were 
designated to provide standards for optimum patient care. 
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VII. Figure References and Legends 
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Figure 1. CHAMP Enrollment by Hospital Cardiac 
Capability. This pie chart depicts the percent of total patients 
randomized into CHAMP that were initially admitted to each 
of the three hospital types. The three hospital types are 























Figure 2. CHAMP Enrollment 1993-1998. This graph 
depicts the percent of total patients randomized into the 























Figure 3. Total CABG (Within 90 Days) Post-MI by 
Year. This graph depicts the percent of patients 
randomized into the CHAMP study that were treated with 
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Figure 4. Early (Within 14 Days) vs. Later (Between 14-90 Days) 
CABG Post-MI by Hospital Type. This graph depicts the percent 
of CHAMP study patients that underwent cardiac surgery within 
14 days of index MI and the percent that underwent cardiac 
surgery between 14-90 days after index MI as well as the total 
percent of patients that underwent cardiac surgery within 90 days 
of infarct MI. 
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p-value for linear trend 
Group 1 p = 0.233 
Group 2 p = 0.021 
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Figure 5. Early CABG (Within 14 Days Post-MI) by 
Hospital Type by Year. This graph depicts the percent of 
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Figure 6. Later CABG (Between 14-90 Days) Post-MI by 
Hospital Type by Year. This graph depicts the percent of 
























p-value for linear trend 
1993 1994 
1 Group 1 
1995 1996 1997 
1 Group 2 i Group 3 
Figure 7. Total CABG (Within 90 Days) Post-Ml by 
Hospital Type by Year. This graph depicts the percent of 
CHAMP study patients treated with CABG within 90 days 
after index ML 
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Figure 8. Total PTCA (Within 90 days) Post-Mi by Year. 
This graph depicts the percent of CHAMP study patients 
that were treated with PTCA within 90 days of infarct MI 
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Figure 9. Early (Within 14 days) vs. Later (Between 14-90 Days) 
PTCA Post-MI by Hospital Type. This graph depicts the percent 
of CHAMP study patients treated with “early” or “later” PTCA as 
well as the total percent of patients that underwent PTCA within 
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Figure 10. Early PTCA (Within 14 Days) Post-MI by 
Hospital Type by Year. This graph depicts the percent of 
CHAMP study patients treated with “early” PTCA. 
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p-value for linear trend 
Group 1 p=0.001 
Group 2 p=0.102 
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Figure 11. Later PTC A (Between 14-90 Days) Post-Mi by 
Hospital Type by Year. This graph depicts the percent of 
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Figure 12. Total PTCA (Within 90 Days) Post-MI by 
Hospital Type by Year. This graph depicts the percent of 
CHAMP study patients that were treated with PTCA within 
90 days of index MI divided according to the hospital type 
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Figure 13. Thrombolytic Use by Year. This graph depicts 
the percent of CHAMP study patients treated with 
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Figure 14. Thrombolytic Use by Hospital Type. This 
graph depicts the percent of CHAMP study patients 
treated with thrombolytics divided according to the 
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Figure 15. Thrombolytic Use by Hospital Type by 
Year. This graph depicts the percent of CHAMP study 
patients treated with thrombolytics divided according to 
the hospital type to which they were admitted and 
depicted over time. 
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Figure 16. ACE Inhibitor Use by Year. This graph 
depicts the percent of CHAMP study patients treated with 
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Figure 17. ACE Inhibitor Use by Hospital Type. This 
graph depicts the percent of CHAMP study patients 
treated with ACE inhibitors divided according to the 
hospital type to which they were admitted. 
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p-value for linear trend 
Group 1 p = 0.029 
Group 2 p = 0.001 
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Figure 18. ACE Inhibitor Use by Hospital Type by Year. This 
graphs depicts the percent of CHAMP study patients treated with 
ACE inhibitors according to the hospital type to which they were 
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Figure 19. Beta-Blocker Use by Year. This graph depicts 
the percent of CHAMP study patients treated with beta- 
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Figure 20. Beta-Blocker Use by Hospital Type. This 
graph depicts the percent of CHAMP study patients 
treated with beta-blockers divided according to the 
hospital type to which they were admitted. 
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p-value for linear trend 
Group 1 p = 0.001 
Group 2 p = 0.001 
Group 3 p = 0.001 
H Group 1 ■ Group 2 1 Group 3 
Figure 21. Beta-Blocker Use by Hospital Type by Year. This graphs 
depicts the percent of CHAMP study patients treated with beta- 
blockers according to the hospital type to which they were admitted 
and depicted over time. 
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Figure 22. Calcium Channel Blocker Use by Year. This 
graph depicts the percent of CF1AMP study patients 
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_Calcium Channel Blocker Use_ 
■ Group 1 1 Group 2 El Group 3 
Figure 23. Calcium Channel Blocker Use by Hospital 
Type. This graph depicts the percent of CHAMP study 
patients treated with calcium channel blockers divided 




p-value for linear trend 
Group 1 p = 0.001 
Group 2 p = 0.001 
Group 3 p = 0.001 
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Figure 24. Calcium Channel Blocker Use by Hospital Type by Year. 
This graphs depicts the percent of CHAMP study patients treated with 
calcium channel blockers according to the hospital type to which they 






















Figure 25. Digitalis Use by Year. This graph depicts the 
percent of CFtAMP study patients treated with digitalis for 
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Figure 26. Digitalis Use by Hospital Type. This graph 
depicts the percent of CHAMP study patients treated with 
digitalis divided according to the hospital type to which 
























p-value for linear trend 
Group 1 p = 0.077 
Group 2 p ^ 0.851 
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H Group 1 □ Group 2 □ Group 3 
Figure 27. Digitalis Use by Hospital Type by Year. This graphs 
depicts the percent of CHAMP study patients treated with digitalis 
according to the hospital type to which they were admitted and 
depicted over time. 
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Figure 28. Diuretic Use by Year. This graph depicts the 
percent of CHAMP study patients treated with diuretics 
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Diuretic Use 
i Group 1 □ Group 2 0 Group 3 
Figure 29. Diuretic Use by Hospital Type. This graph 
depicts the percent of CHAMP study patients treated with 
diuretics divided according to the hospital type to which 
they were admitted. 
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p-value for linear trend 
Group 1 p = 0.212 
Group 2 p = 0.895 
Group 3 p = 0.966 
1993 1994 1995 1996 1997 
□ Group 1 □ Group 2 1! Group 3 
Figure 30. Diuretic Use by Hospital Type by Year. This graphs 
depicts the percent of CHAMP study patients treated with 
diuretics according to the hospital type to which they were 
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Figure 31. Nitrate Use by Year. This graph depicts the 
percent of CFiAMP study patients treated with nitrates 
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Figure 32. Nitrate Use by Hospital Type. This graph 
depicts the percent of CFIAMP study patients treated 
with nitrates divided according to the hospital type to 
which they were admitted. 
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p-value for linear trend 
Group 1 p = 0.005 
Group 2 p = 0.109 
Group 3 p = 0.001 
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Figure 33. Nitrate Use by Hospital Type by Year. This graphs 
depicts the percent of CHAMP study patients treated with nitrates 
according to the hospital type to which they were admitted and 
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Figure 34. Hypolipidemic Agent Use by Year. This graph 
depicts the percent of CHAMP study patients treated with 
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p = 0.001 
Hypolipidemic Agent Use 
Figure 35. Hypolipidemic Agent Use by Hospital Type. 
This graph represents the percent of CHAMP study 
patients treated with hypolipidemic agents divided 




p-value for linear trend 
Group 1 p = 0.001 
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Figure 36. Hypolipidemic Agent Use by Hospital Type by Year. This 
graphs depicts the percent of CHAMP study patients treated with 
hypolipidemic agents according to the hospital type to which they were 




Table A. CHAMP Exclusion Criteria 
Life expectancy of less than 2 years due to the presence of advanced organ disease or 
malignancy 
The presence of ongoing bleeding or a known predisposition to bleeding such as an 
acquired or inherited coagulopathy, thrombocytopenia (platelet count < 100,000/mm3), 
active peptic ulcer disease, a history of clinically significant gastrointestinal bleeding, 
severe liver disease associated with coagulopathy, dialysis dependent end stage renal 
disease, or the presence of grade 3 or 4 retinal hemorrhages 
The presence of an alternative indication for anticoagulant therapy including any of the 
following: a cerebral vascular accident complicating the index AMI, the presence of a 
left ventricular clot, an acute venous thrombosis or pulmonary embolism, the presence 
of atrial fibrillation or cardiac valve replacement 
The presence of a condition requiring treatment with nonsteroidal antiinflammatory 
drugs or with ASA in doses exceeding 80 mg/d (i.e. rheumatoid arthritis) 
Severe uncontrolled hypertension with systolic blood pressure in excess of 180 mm Hg 
or diastolic blood pressure in excess of 110 mm Hg at time of consideration for 
randomization. Patients excluded with this condition were able to be rescreened once 
the blood pressure had been controlled 
Personal considerations making follow-up difficult or impractical such as living too far 
from the center, the presence of severe mental disturbances, or substance abuse 
Known hypersensitivity to aspirin or history of significant hemorrhage attributed to 
aspirin or warfarin therapy in the past 
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Ta 3le B. Information Collected From CHAMP Database 
CHAMP Rates of procedure utilization: Rates of medication usage: 
Enrollment Early (within 14 days post-MI) CABG Thrombolytics 
Later (between 14-90 days post-MI) CABG Ace inhibitors 
Early (within 14 days post-MI) PTC A Beta-blockers 





Table C. Classification System of Hospital Sophistication 
Type 1 No cardiac catheterization 
No cardiac surgery 
Type 2 Yes cardiac catheterization 
No cardiac surgery 
Type 3 Yes cardiac catheterization 
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